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Protein synthesis in archaebacteria and the cytoplasm of eukaryotes is initiated 
using the initiator methionyl-tRNA (Met-tRNAiMet). In contrast, formylated methionyl-
tRNA (fMet-tRNAiMetf) is found in eubacteria, and in chloroplasts and mitochondria of 
eukaryotes, and this formylated initiator tRNA was widely believed to be required for 
initiation of protein synthesis in those systems. However, the fact that initiation of protein 
synthesis in yeast mitochondria can occur with unformylated initiator tRNA has changed 
our perspective about the initiation of mitochondrial protein synthesis. This dissertation is 
composed of two parts. Part I describes an investigation of the yeast AEP3 gene which 
was isolated by a genetic screening system in Saccharomyces cerevisiae. The main goal 
of this part was to discover new accessory factor(s) that might be involved in initiation of 
protein syntheis of yeast mitochondria when there is no formylation of initiator tRNA and 
determine how they support the initiation process in Saccharomyces cerevisiae. The 
 vii
synthetic petite genetic screen identified the AEP3 gene. Protein-protein binding assays 
as well as protein-initiator tRNA binding assays indicate that Aep3p is associated with 
the initiation process in yeast mitochondrial protein synthesis. This discovery is important 
because it suggests the possible mechanism by which initiation of protein synthesis in 
yeast mitochondria occur under conditions where there is no formylation of initiator 
tRNA. Part II describes a study of the TRM5 gene encoding a tRNA methyltransferase in 
S. cerevisiae. The TRM5 gene encodes a tRNA (guanine-N1-)-methyltransferase (Trm5p) 
previously known to methylate guanosine at position 37 (m1G37) in certain cytoplasmic 
tRNAs in S. cerevisiae. The main goal of this part was to investigate whether Trm5p is 
also responsible for m1G37 modification of mitochondrial tRNAs. Full-length Trm5p, 
purified as a fusion protein with maltose-binding protein, exhibited robust 
methyltransferase activity with tRNA isolated from a ∆trm5 mutant strain, as well as with 
a synthetic mitochondrial tRNAMetf and tRNAPhe. High pressure liquid chromatography 
analysis showed the methylated product to be m1G. Analysis of subcellular fractionation 
and immunoblotting revealed that the enzyme was localized to both cytoplasm and 
mitochondria. Our data including the analysis of N-terminal truncation mutants suggest 
that this tRNA modification plays an important role in reading frame maintenance in 
mitochondrial protein synthesis.  
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PART I 
Chapter 1:  Introduction 
Protein synthesis is carried out by ribosomes, which act as RNA-based enzymes 
(ribozymes) to catalyze the formation of peptide bonds. The ribosome consists of a small 
and a large subunit; 30S and 50S in prokaryotes or 40S and 60S in eukaryotes, 
respectively. The two subunits are assembled into a functional ribosome. Ribosomes can 
initiate translation on the messenger RNA (mRNA) that contains the genetic information. 
Translation is usually divided into three stages: Initiation, elongation and termination. 
Translation initiation is the rate-determining step and requires several initiation factors to 
assemble together with ribosomes and initiator-tRNA (Met-tRNAiMet). The ribosome 
possesses three tRNA binding sites: the exit (E), peptidyl (P), and amino-acyl (A) sites. 
During the initiation stage, two ribosome subunits are assembled together, along 
with several different initiation factors (IF1, IF2 and IF3) and cofactors (initiator-tRNA, 
GTP), to search for the initiation recognition site. In the elongation stage, an incoming 
aminoacyl-tRNA is delivered to the A site of the ribosome with elongation factor EF-Tu-
GTP. Along with several other elongation factors (EF-Tu and EF-G), the ribosome reads 
the messenger RNA (mRNA) to generate polypeptide chains. Elongation ends when a 
stop codon on the mRNA is reached. Then, the process goes into the termination stage of 
protein synthesis. Finally, the newly synthesized protein is released from the ribosome. 
Among three stages in protein synthesis, the initiation stage is the rate-limiting 
step and most highly regulated. Moreover, the mechanism by which the initiation of 
protein synthesis occurs is best understood in bacteria. The bacterial 70S ribosome 
comprises two subunits: a large 50S and a small 30S subunit. The aminoacyl charged 
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tRNA containing an anticodon that is complementary to a codon for that amino acid on 
mRNA is brought to the ribosome. The initiation process in bacteria is depicted in Figure 
1.1. The initiation factor 3 (IF3) binds to the 30S ribosomal subunit to promote 
dissociation of the 70S ribosome as well as to prevent the association with 50S ribosomal 
subunit. Initiation factor 1 (IF1) binds to the 30S small subunit to prevent the premature 
binding of an amino-acyl tRNA corresponding to the A site of 30S ribosome (Moazed et 
al., 1995), also directing the initiator tRNA to the ribosomal P site (Carter et al., 2001; 
Dahlquist and Puglisi, 2000). A GTP-bound initiation factor 2 (IF2) forms a complex 
with an initiator tRNA (fMet-tRNAiMetf), bringing it to the P site of 70S ribosome (Wu 
and RajBhandary, 1997). IF2 is one of the largest initiation factors, which can be divided 
into several domains: the N domain, G domain and C domain (Figure 1.2). The N domain 
contains a less highly conserved region (Sorensen et al., 2001; Steffensen et al., 1997). 
The G domain is the site where GTP binding occurs, and it is highly conserved across 
archaea, bacteria, and eukaryotes. The C domain contains the binding site for fMet-
tRNAiMetf (Spurio et al., 2000). The 30S preinitiation complex resulting from assembly of 
30S small subunit, three initiation factors, and mRNA is relatively unstable. Afterward a 
conformational change occurs to promote the interaction between codon and anticodon, 
and then the pre-initiation complex becomes stable (Gualerzi and Pon, 1990; McCarthy 
and Brimacombe, 1994). IF1 and IF3 are released from the complex, while IF2 promotes 
the association of the large 50S subunit to the complex. Once initiator fMet-tRNAiMetf is 
bound in the correct position in the P site, IF2 is released from the complex by the 
hydrolysis of GTP. Finally, the 50S subunit binds to the 30S subunit to form the 70S 
ribosome.  
 3
 
 
 
Figure 1.1:  Overview of initiation of protein synthesis in prokaryotes. The initiation 
factor 3 (IF3) and initiation factor 1 (IF1) bind to the 30S small subunit. 
Once the preinitiation complex formed with GTP-bound IF2 along with 
fMet-tRNAiMetf becomes stable, IF3 and IF1 are released from the complex, 
followed by the release of IF2 with the hydrolysis of GTP. Finally, the 50S 
large subunit binds to the 30S subunit, forming the 70S ribosome. Blue-
shaped: IF3, Red-shaped: IF1, Purple-shaped: IF2.  
 4
 
 
 
 
 
 
 
 
 
Figure 1.2:  Map of domain structure of initiation factor 2. C domain is highlighted in 
red color. Numbers indicate amino acid positions. 
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The mechanism of initiation of protein synthesis in eukaryotic cytoplasm is quite 
complicated compared with that in prokaryotes. Briefly, to initiate translation, the small 
ribosomal subunit (40S) is assembled with a ternary complex containing eukaryotic 
initiation factor 2 (eIF2), Met-tRNAiMet, and GTP (Sonenberg, et al., 2000). The resulting 
43S preinitiation complex is recruited to the mRNA through interactions with eIF4 
factors which bind the cap structure of the mRNA (Marcotrigiano et al., 1997; Matsuo et 
al., 1997; Tomoo et al., 2002). The 43S complex then is thought to scan along the 5’UTR 
of the mRNA until it encounters the first start AUG codon (Kozak, 1999, 2002). 
Following the recognition of AUG, the 60S subunit joins to form the complete 80S 
ribosome.  
Mitochondria of eukaryotes have their own DNA which is expressed by specific 
transcription and translation systems (Attardi, 1985). Mammalian mitochondria contain 
two ribosomal subunits; 28S for the small subunit and 39S for the large subunit (O’Brien, 
et al., 1976). In addition, three elongation factors were purified and characterized (Chung 
and Spremulli, 1990; Schwartzbach and Spremulli, 1989). In mammalian mitochondria, 
the mitochondrial mRNAs lack a 5’ leader or cap structure, suggesting that the 
mitochondrial ribosome does follow the mechanism of a cap binding and scanning for 
initiation of protein synthesis found in the eukaryotic cytoplasm. Mitochondrial initiation 
factor 2 and initiation factor 3 in bovine mitochondria were purified and characterized 
(Koc and Spremulli, 2002; Liao and Spremulli, 1991). Based on these experimental data, 
initiation of protein synthesis in mitochondria of eukaryotes has been thought to be much 
more similar to the initiation of protein synthesis in prokaryotes than to that of in 
eukaryotic cytoplasm. Therefore, the model for initiation in bacteria is used to understand 
the mechanism by which the initiation of protein synthesis in mitochondria is processed 
(Gualerzi and Pon, 1990).  
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The following literature review focuses on the formylation of initiator tRNA 
(fMet-tRNAiMetf) and the effect of unformylated initiator tRNA (Met-tRNAiMet) in 
Saccharomyces cerevisiae mitochondria. For your convenience, the introduction part is 
divided into four sections. First, general information about the formylation of Met-
tRNAiMetf is described. Second, the discovery of the fact that fMet-tRNAiMetf is not 
necessary for initiation of protein synthesis in S.cerevisiae is discussed. Third, 
characterization of yeast mitochondrial initiation factor 2 (ymIF2) is described. Finally, 
the purpose of this study is summarized.  
 
1.1 Formylation of initiator tRNA in mitochondria 
The discovery and subsequent characterization of formylation of initiator tRNA 
gave an insight into the mechanism by which initiation of protein synthesis is processed. 
In all organisms, protein synthesis is initiated with methionine or formylmethionine 
(Kozak, 1983; RajBhandary, 1994). Two types of methionine tRNA have been found in 
all organisms. The cytoplasmic protein synthesis systems of eukaryotes initiate with 
methionine. In eubacteria such as E.coli, it was found that N-formylmethionine (Figure 
1.3) is used to initiate protein synthesis (Marcker and Sanger, 1964). The authors found 
that N-formylmethionyl-tRNA (fMet-tRNAfMet) was generated from methionyl-tRNA 
(Met-tRNAMet) by enzymatic reaction. Also, they found an unknown compound when 
they isolated tRNAs from E.coli cells, that was identical with N-formylmethionine by 
chemical hydrolysis and chromatography analyses. As a result, they concluded that the 
eubacterial protein synthesis is initiated with formylmethionine. Several other 
experimental data also supported that protein synthesis is initiated with 
formylmethionine. Eukaryotic organelles such as mitochondria in Neurospora crassa 
contained a formylated methionine (Epler et al., 1970). The authors investigated both 
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mitochondrial and cytoplasmic extracts for fMet-tRNA. What they found was that a Met-
tRNA isolated from mitochondria was formylated with an E.coli extract, but the 
corresponding cytoplasmic Met-tRNA could not be. Using chromatographic analysis, 
mitochondrial fMet-tRNA is separated from Met-tRNA. Therefore, they concluded that 
mitochondrial protein synthesis involves a formylated methionine. In addition, N-
formylmethionyl-tRNA was identified in Hela cells (Galper and Darnell, 1969). Total 
RNA obtained from Hela cells was incubated with [14C] methionine, then subjected to 
RNase digestion and electrophoresis analysis. They found that formylmethionine was 
attached to terminal adenosine in RNA of Hela cells. The tRNA was the only known 
form of RNA which attached amino acids to terminal adenosine. The mitochondrial 
fractions obtained from Saccharomyces cerevisiae contained fMet-tRNA (Halbreich and 
Rabinowitz, 1971). This fraction showed a formyltetrahydrofolic acid: Met-tRNA 
formylase activity (Figure 1.4). No such activity was detected in cytoplasmic supernatant 
in yeast. This formylase was most active with mitochondrial Met-tRNA, but not active 
with yeast cytoplasmic tRNAs. The authors suggested that fMet-tRNA is exclusively 
localized to the mitochondria in yeast. Schwartz et al. (1967) isolated N-
formylmethionine from proteins synthesized in Euglena chloroplasts (Schwartz et al., 
1967). They showed that the amino-terminal peptide which was digested by 
chymotrypsin appeared to be identical to the peptide isolated from E.coli extracts. 
Therefore, they concluded that the initiation of protein synthesis in chloroplasts is very 
similar to that which occurs at E.coli. fMet-tRNA was also detected in yeast and rat 
mitochondria, but not in the corresponding cytoplasmic systems (Smith and Marcker, 
1968). 
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There is additional evidence that protein synthesis in eukaryotic mitochondria and 
chloroplasts is initiated with formylmethionine in experiments using puromycin. 
Puromycin is an inhibitor of protein translation causing the premature chain termination 
during translation (Nathans, 1964). Bianchetti et al. (1971 and 1977) investigated whether 
yeast mitochondria can synthesize peptide chains with formylmethionine at the N-
terminus in vitro. What they found was that isolated mitochondria of yeast contained 
formylmethionyl-puromycin derivatives in the presence of system containing amino 
acids, formyl group donors, and puromycin. Their data indicated that polypeptide chains 
start with formylmethionine (Bianchetti et al., 1977; Bianchetti et al., 1971). In addition, 
using radioactive formate, Feldman et al. (1974) tested whether the mitochondrial protein 
synthesis utilizes fMet-tRNA in initiation. They found that formate labeled nascent 
polypeptide chains on mitochondrial ribosomes in yeast, and by pretreatment with 
puromycin, N-formylmethionyl-puromycin was formed. Also, when yeast cells were 
labeled with formate, they isolated mitochondrial membranes and did a complete 
proteolysis. Analysis of amino acids showed that label was found in N-formylmethionine 
(Feldman and Mahler, 1974; Mahler et al., 1972). Galper et al. (1971) also used 
puromycin to investigate whether fMet-tRNA is present in HeLa cells. They speculated 
that fMet-tRNA might function as an initiator for mitochondrial protein synthesis, and 
they used puromycin to test whether protein synthesis was initiated with fMet-tRNA. 
Cycloheximide is an inhibitor of cytoplasmic protein synthesis, but mitochondrial protein 
synthesis is resistant to cycloheximide (Hawley and Greenawalt, 1970). They found that 
treatment with puromycin resulted in fMet-puromycin, and the production of fMet-
puromycin was insensitive to cycloheximide (Galper and Darnell, 1971). Sala et al. 
(1970) used an assay to test whether the mitochondrial ribosomes in N. crassa contained 
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fMet-puromycin, and they also observed the formation of fMet-puromycin (Sala and 
Kuntzel, 1970).  
 Other work showed that several mitochondrially synthesized proteins in S. 
cerevisiae, N. crassa, and beef heart mitochondria contained N-formylmethionine at their 
N-terminus (Beechey et al., 1967; Chomyn et al., 1981; Sebald et al., 1979; Steffens and 
Buse, 1979; Tzagoloff et al., 1979; Walker et al., 1991).  
Taken together, these results led to the dogma that initiation of protein synthesis 
in mitochondria requires formylated initiator tRNA as in eubacteria. Studies of bovine 
mitochondria initiation factor 2 (bmIF2) further supported this dogma. Liao et al. (1991) 
showed that the bmIF2 promoted the binding of fMet-tRNAiMetf to the mitochondrial 
ribosomes in an in vitro assay (Liao and Spremulli, 1991), and it showed a 50-fold 
binding preference for fMet-tRNAiMetf over Met-tRNAiMet (Spencer and Spremulli, 2004).   
The enzyme that is responsible for the formylation of initiator tRNA is a 
methionyl-tRNA formyltransferase (Figure 1.3). It is specific for the initiator tRNA (Lee 
et al., 1991; Schmitt et al., 1998). This enzyme has been reported in the mitochondria of 
several species including S. cerevisiae, N. crassa, and Hela cells (Epler et al., 1970; 
Galper and Darnell, 1969; Halbreich and Rabinowitz, 1971). In S. cerevisiae, the FMT1 
gene encodes this enzyme. The yeast enzyme is composed of 393 amino acids and has 
approximately 30% amino acid sequence identity to the eubacterial and bovine 
mitochondrial homologs (Takeuchi et al., 1998).  
The formyl group for the methionyl-tRNA formyltransferase reaction is donated 
by 10-formyl THF (Dickerman et al., 1967) (Figure 1.3). Yeast mitochondria can 
synthesize 10-formyl-THF via the activities of the mitochondrial trifunctional C1-THF 
synthase encoded by MIS1 gene (Shannon and Rabinowitz, 1988).  
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The effect of formylation of initiator tRNA on protein synthesis has shown 
different results depending on species. In E.coli, a strain deleted for the gene encoding 
methionyl-tRNA formyltransferase showed severe growth defects (Guillon et al., 1992; 
Meinnel et al., 1993; Varshney and RajBhandary, 1992). On the other hand, initiation of 
protein synthesis in Pseudomonas aeruginosa does not require the formylation of Met-
tRNAiMet, indicating that formylation is not necessary for all bacteria (Newton et al., 
1999).  
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1.2 Unformylation of initiator tRNA in yeast mitochondria 
The first hint that mitochondrial protein synthesis might not absolutely require 
formylated initiator tRNA came from studies of the MIS1 gene, encoding the 
mitochondrial C1-THF synthase in yeast (Figure 1.4). Disruption of the MIS1 gene had no 
effect on growth on non-fermentable carbon sources (Shannon and Rabinowitz, 1988). 
This was surprising since growth on non-fermentable carbon sources such as glycerol and 
ethanol requires respiration and functional mitochondria. Mitochondrial protein synthesis 
is required for functional mitochondria (Tzagoloff and Dieckmann, 1990), since several 
of the respiratory chain components are synthesized on mitochondrial ribosomes. In 
yeast, respiratory-incompetent mutants are easily detected, as they form small colonies 
(petites) on glucose (growth by fermentation only), and are unable to grow at all on non-
fermentable carbon sources.  
A second clue came from a report that disruption of the FMT1 gene, encoding a 
methionyl-tRNA formyltransferase, also had no effect on growth. Deletion of the FMT1 
gene had no effect on viability (Skala et al., 1992), suggesting that FMT1 is not essential. 
Li et al. (2000) directly tested the hypothesis that these mutant yeast strains lacked 
formylated initiator tRNA in their mitochondria. Using a sensitive gel assay to 
distinguish formylated from unformylated initiator tRNA, fMet-tRNAiMetf was 
undetectable in ∆fmt1 or ∆mis1 or ∆fmt1mis1 double deletion strains. However, all of 
these mutant strains grew on non-fermentable carbon sources, suggesting mitochondrial 
protein synthesis was initiating with unformylated initiator tRNA. Tibbetts et al. (2003) 
then showed that mitochondria from these strains lacking formylated initiator tRNA did 
indeed carry out protein synthesis in vivo.  
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1.3 Characterization of yeast mitochondria initiation factor 2 (ymIF2) 
The discovery that protein synthesis can be initiated with unformylated initiator 
tRNA (Met-tRNAiMet) in yeast mitochondria led the Appling lab to explore the initiation 
process more closely. Therefore, yeast mitochondrial initiation factor 2 (ymIF2) was 
cloned, purified, and characterized (Garofalo et al., 2003). IF2 is a central factor in the 
initiation process and is highly conserved across bacteria, archaeabacteria, and eukaryotes 
(Roll-Mecak et al., 2001). In S. cerevisiae, the IFM1 gene encodes the mitochondrial IF2 
consisting of 676 amino acids and a mitochondrial presequence (Figure 1.2). Using 
biochemical analyses, purified ymIF2 showed functional characteristics quite similar to 
bacterial IF2s (Garofalo et al., 2003). YmIF2 bound fMet-tRNAiMetf, and delivered it to 
the ribosome. It also bound to Met-tRNAiMetf, but showed a 6 times higher binding 
preference for fMet-tRNAiMetf versus unformylated initiator tRNA. YmIF2 contains 
ribosome-dependent GTPase activity. Overall, ymIF2 did not appear to function 
differently from other IF2s in those in vitro assays. However, genetic analyses with 
ymIF2 showed unexpected results. Tibbetts et al. (2003) showed that mitochondrial 
translation products in S. cerevisiae were synthesized normally in the absence of 
formylated initiator tRNA. The yeast strain containing the deletion of IFM1 gene (∆ifm1) 
which encodes the ymIF2 was unable to grow on non-fermentable carbon source, 
indicating that the strain has defective mitochondrial protein synthesis. However, when a 
construct either harboring the yeast IFM1 gene or a cDNA encoding bovine 
mitochondrial IF2 (bmIF2) was transformed into the ∆ifm1 strain, each construct 
complemented the respiratory defect, suggesting that bmIF2 is able to replace ymIF2 and 
support the mitochondrial function in yeast in vivo. They then tested whether the bmIF2 
can support mitochondrial function under conditions where there is no formylation of 
initiator tRNA. They used the strain lacking the FMT1 gene which encodes the 
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methionyl-tRNA formyltransferase, and confirmed that this strain did not contain fMet-
tRNAfMet. The plasmid expressing bmIF2 was transformed into the double mutant strain 
(∆ifm1∆fmt1), followed by sporulation and tetrad dissection to isolate a spore carrying 
the plasmid. This transformant grew on YPEG medium, indicating that bmIF2 can 
replace ymIF2 in vivo even when there is no formylation of initiator tRNA (Tibbetts et 
al., 2003). This result was a surprise because purified bmIF2 showed a 50-fold higher 
binding preference for fMet-tRNAiMetf over Met-tRNAiMetf in binding assay in vitro (Liao 
and Spremulli, 1991).  
 
1.4 The purpose of present study 
The discrepancy between these in vitro and in vivo results led us to hypothesize 
that there are accessory factors that become essential for mitochondrial protein synthesis 
under conditions when fMet-tRNAiMetf  is low or absent.  
To search for these factors, the genetic screening system called synthetic petite 
screen was designed (Bender and Pringle, 1991). The basic principle of this screen is that 
mutations in two genes, which by themselves do not cause a mutant phenotype, in 
combination do cause a mutant phenotype (Appling, 1999). We used this screen to search 
for accessory factors that support the initiation of protein synthesis with unformylated 
Met-tRNAiMetf . If these factors exist in yeast, we can look to see whether they exist in 
higher organisms as well. YmIF2 is the only "factor" involved in the initiation of yeast 
mitochondrial protein synthesis that has been identified and characterized. Other factors 
involved in mitochondrial protein synthesis have been characterized from mammals (such 
as the bovine mitochondrial IF2 and IF3) (Koc and Spremulli, 2002; Ma and Spremulli, 
1996), but no homologs of IF1 and IF3 exist in the yeast genome. Therefore, the genetic 
screen might also identify mitochondrial proteins with IF1- or IF3-like initiators. 
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Figure 1.3:  Transfer of formyl group to initiator tRNA in S. cerevisiae mitochondria. 
The C1-THF synthase encoded by the MIS1 gene converts 5,10-methenyl 
THF to 10-formyl THF, and the methionyl-tRNA formyltransferase encoded 
by FMT1 gene catalyzes the transfer of formyl group to Met-tRNAiMetf. 
Formylmethionine is indicated as a dotted-circle.  
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Figure 1.4:  Overview of One-carbon cycle pathway in S. cerevisiae. Two parallel 
enzymes, C1-THF synthase, encoded by ADE3 gene in cytoplasm and by 
MIS1 gene in mitochondria in yeast. A formyl group is highlighted by red 
color.  
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Chapter 2:  Experimental Procedures 
The experimental methods used for the yeast genetic screening system and for 
analysis of the AEP3 gene are described in the following sections. Yeast strains and 
plasmids used in this study were summarized in Appendix C and D.  
 
2.1 Yeast strains, materials, and media 
The Saccharomyces cerevisiae strains used in this part are summarized in 
Appendix C. Strain Y03039 was obtained from the European Saccharomyces Cerevisiae 
Archive for Functional Analysis (EUROSCARF, Frankfurt, Germany). The following 
materials and reagents were used: yeast media (Difco laboratories), 5-fluoorotic acid (5-
FOA, BioVectra DCL, Charlottetown, CA), KOD Hot Start DNA polymerase (Novagen, 
Gibbstown, NJ), restriction enzymes (New England Biolabs, Ipswich, MA), 
[35S]methionine (PerkinElmer Life Sciences, Boston, MA), Geneticin (G-418 sulfate, 
American Bioanalytical, Natick, MA). General chemicals, of the highest grade 
commercially available, were obtained from Sigma (St. Louis, MO), Fisher Scientific 
(Fair Lawn, NJ), or VWR (West Chester, PA) and used without further purification.  
Media contained 1% yeast extract, 2% Bacto-peptone, and either 2% glucose 
(YPD) or 2% ethanol and 3% glycerol as carbon sources (YPEG). Synthetic minimal 
media (YMD) contained 0.7% yeast nitrogen base without amino acids, 2% glucose as 
carbon sources and was supplemented for necessary growth as follows (final 
concentration): L-leucine (30 mg/liter), L-lysine (30 mg/liter), L-methionine (20 
mg/liter), L-histidine (20 mg/liter), and uracil (20 mg/liter). For solid media plates, 2% 
Bacto-agar was added (Chan and Appling, 2003).  
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The radioactive initiator tRNAs ([35S]fMet-tRNAfMet and [35S]Met-tRNAiMet) and 
[14C]Lys-tRNALys were generous gifts from Dr. Gisela Kramer (the University of Texas 
at Austin).  
 
2.2 Screen for mutations creating a synthetic petite phenotype with ∆fmt1 
The wild-type FMT1 gene containing both 300 base pairs of the 5’UTR (upstream 
of the start codon for the FMT1 gene) and 100 base pair 3’UTR (downstream of the stop 
codon) was amplified by PCR using primers: 5’-
CAGTGGATCCACACCCAATTGCGAGCCTAA-3’ (FMT1f2; BamHI site is 
underlined) and 5’-GTAGATCGATATGTAGAGCCGGGTTACAGG-3’ (FMT1r2; ClaI 
site is underlined). The resulting fragment was digested with restriction enzymes, BamHI 
and ClaI, and inserted into enzyme-cleaved pRS416, a low-copy CEN4 URA3 plasmid 
(Sikorski and Hieter, 1989) obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) to generate pRS416-FMT1. Strain Y03039 was transformed with 
pRS416-FMT1, and the resulting transformants were exposed to UV radiation (Protocol 8 
in Appendix E; performed by Dr. Anne Tibbetts at the University of Texas at Austin) to 
generate random mutations on the strain (Figure 2.1). Mutagenized cells were spread onto 
200 complete nonfermentable carbon source medium plates (YPEG: No.1, Figure 2.1) to 
isolate single colonies and incubated at 30oC for 6 days. These plates were replica-plated 
onto 200 5-flouroorotic acid (5-FOA) plates containing glucose as a carbon source to 
evict the URA3 plasmids from the cells. The cells lacking the pRS416-FMT1 plasmid 
were replica-plated onto another 200 complete nonfermentable carbon source medium 
plates (YPEG: No.2, Figure 2.1). Potential synthetic petite mutants grew on YPEG 
(No.1), before the loss of pRS416-FMT1 plasmid, but not on YPEG (No.2), after the loss 
of pRS416-FMT1 plasmid. As a result, eight synthetic petite mutants were isolated from 
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this screen and tested whether the phenotype of the synthetic petite (s.p.) mutants was 
caused by a recessive nuclear mutation.  
 
2.3 Isolation and identification of a gene interacting with ∆fmt1 
Synthetic petite mutants were individually transformed with yeast genomic DNA 
libraries of S.cerevisiae (ATCC) to find a functional gene that corresponds to the 
mutation causing the synthetic petite phenotype. Cells were spread onto 70 minimal 
medium plates containing histidine and methionine, and then replica-plated onto another 
70 plates containing 5-FOA as well as both ethanol and glycerol as nonfermentable 
carbon sources. The respiratory competent transformants were isolated, and then 
restreaked onto 5-FOA/YPEG plates to confirm whether transformants can complement 
the phenotype of petite mutants. Complementary plasmids were rescued from synthetic 
mutant strains (Protocol 7 in Appendix E). Identification of the genomic fragment inserts 
was determined by sequencing using plasmid specific primers flanking the insert: 
AJO194 (5’-GCTACTTGGAGCCACTATCGACTAC-3’) and AJO195 (5’-
CAGCAACCGCACCTGTGG-3’) (obtained from Dr. Arlen Johnson, the University of 
Texas at Austin). The obtained DNA sequence was BLASTed against the Saccharomyces 
cerevisiae Genome Database (SGD) to identify the chromosomal locus.  
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Figure 2.1:   Overall scheme for synthetic petite screen.  
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2.3.1 Tetrazolium chloride overlay assay (TTC) to analyze respiration deficiency of 
the synthetic petite mutants 
For the TTC assay (Ogur et al., 1957), each synthetic petite mutant strain was 
transformed with a plasmid containing the identified gene, and was spread onto minimal 
medium plates, and incubated at 30oC for 3 days to generate the transformants. About 2 
ml of sodium phosphate buffer (pH 7.0) containing 1.5% Bacto-Agar and 0.1% 
tetrazolium chloride was poured onto a transformants-contained plate, and then incubated 
at room temperature for 3 hours.  
 
2.3.2 Construction of a pRS415-AEP3 vector and a pRS415-AEP3 mutant vector 
To clone the wild-type AEP3 gene into a plasmid, yeast genomic DNA obtained 
from strain DAY4 was amplified by PCR using KOD Hot Start DNA polymerase 
(Novagen, CA) and two primers; a forward primer 5’-
AGCCTCGAGCCATAGCAGATTATACTA-3’ (A3_FOR; the XhoI site is underlined) 
and a reverse primer 5’-AATGGATCCTTCCTGTCCAAATGC-3’ (A3_REV; the 
BamHI site is underlined).  
For the mutant AEP3 construct, yeast genomic DNA obtained from the synthetic 
petite strain, s.p.175, was isolated by PCR amplification using the same primers above. 
Each construct contained the same 300bp of 5’-UTR and 100bp of 3’-UTR in the AEP3 
genomic DNA, and its sequence was confirmed by DNA sequencing.  
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2.4 Plasmid constructs for the purification of the AEP3 and the mutant gene 
products as MBP fusion proteins 
To generate a MBP-AEP3 fusion protein, the wild-type AEP3 gene was isolated 
by PCR amplification from yeast genomic DNA of DAY4 strain using primers: 5’-
CCGGGATCCATGAATACATTAAGG-3’ (AP3-pMAL-For; BamHI site is underlined 
and start codon is bold) and 5’-CCGAAGCTTTCAAACCTCCCCAAC-3’ (AP3-pMAL-
Rev; HindIII site is underlined and stop codon is bold). PCR was carried out using KOD 
Hot Start DNA polymerase (CalBiochem, Gibbstown, NJ). The resulting PCR fragment 
was digested with BamHI and HindIII, then gel-purified, and inserted into a pRSET A 
vector (Invitrogen, CA) which was pre-cleaved with same enzymes. The AEP3 gene was 
also cloned into the pMALc2H10T vector (a gift from Dr. John Tesmer, University of 
Michigan) (Kristelly et al., 2004) to generate MBP-Aep3p, following the same 
procedures described above. The insert was verified at the DNA Core Facilities of the 
Institute for Cellular and Molecular Biology at the University of Texas at Austin. For the 
mutant constructs, each procedure was the same as for a wild-type construct except for 
isolation of a mutant gene from the synthetic petite mutant strain.  
To express MBP-Aep3 protein, the MBP-Aep3 construct was transformed into 
E.coli Rosetta 2 (DE3) cells (Novagen, Gibbstown, NJ). The resulting transformants were 
placed into Luria Broth containing 50 μg/ml ampicillin, grown to OD600 of 0.4, and 
induced with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 15oC overnight. 
The cells were harvested by centrifugation at 5,000 rpm for 10 min, washed in 1 x 
binding buffer (5 mM imidazole, 0.5 M NaCl, 20 mM Tri-HCl, pH 7.9), centrifugated 
under the same condition, and then kept at -80oC. Cells were resuspended in 50 ml of 1x 
binding buffer, followed by adding a tablet of protease inhibitor (Roche Applied Science, 
Indianapolis, IN). Cells were lysed by sonication on ice 15 sec with 15 sec intervals for 
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six cycles. The supernatant was collected after centrifugation at 17,000 rpm for 30 min, 
and applied to a column filled with 5 ml His·Bind Resin (Novagen, Gibbstown, NJ) that 
had been charged with Ni2+ and equilibrated in 1 x binding buffer containing 5 mM 
imidazole and 0.5 M NaCl in 20 mM Tris-HCl buffer, pH 7.9. After washing with 50 ml 
binding buffer, loosely bound protein was eluted with wash buffer containing 60 mM 
imidazole and 500 mM NaCl in Tris buffer. Tightly bound protein was eluted by 250 mM 
imidazole in the same Tris/NaCl buffer. Fractions of four drops were collected into 1.5 
ml eppendorf tubes, and 1 μl of each fraction was applied to nitrocellulose, followed by 
staining with a solution of Coomassie brilliant R and destaining to identify fractions 
containing eluted protein. The pooled protein fractions eluted with 250 mM imidazole 
were dialyzed against 500 ml of 20 mM Tris-HCl, pH 7.5 for four hours and stored at -
80oC in small aliquots. For the expression of mutant protein, the same procedure was 
used. The concentration of purified proteins was determined by the Bradford protein 
assay (Bradford, 1976), and analyzed by 10% SDS-PAGE (Laemmli, 1970).  
Pure full-length ymIF2 as well as the C2-subdomain of ymIF2 were a generous 
gift from Dr. Gisela Kramer (The University of Texas at Austin) (Garofalo et al., 2005; 
Garofalo et al., 2003).  
 
2.5 In vitro filter binding assay 
The filter binding assay for formation of the binary complex between the wild-
type AEP3 protein or yeast mitochondrial initiation factor 2 (ymIF2) or the AEP3 mutant 
protein and either fMet-tRNAMetf or Met-tRNAMetf or Lys-tRNALys was performed as 
described (Sundari et al., 1976). Different amounts of each protein in 50 μl total reaction 
mixture containing 50 mM Tris-HCl, pH 7.0, 2 mM DTT, and 10 μg BSA was incubated 
with [35S] initiator tRNA (4 pmol) for 20 min on ice. Reactions were stopped with 2 ml of 
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ice-cold solution containing 50 mM Tris-HCl, pH 7.0 and 2 mM DTT, and then filtered 
through nitrocellulose filters, followed by washing 5 times with the same buffer. Filters 
were dried at 150oC of for 4 min, and radioactivity on filters was determined by liquid 
scintillation counting. Each assay was performed in duplicate.  
 
2.6 In vitro Maltose binding protein (MBP) Pull-down assay 
For MBP-Aep3 pull downs, 5 μl of MBP-Aep3 protein (20 pmol) was incubated 
with ymIF2 in the indicated concentrations at room temperature for 2 hours in 200 μl of 
buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 2 mM DTT 
with gentle rotation. About 30 μl of a slurry containing amylose affinity beads (New 
England Biolabs; diluted 50% with 1 x Phosphate Buffer Saline (PBS)) were added to the 
mixture and incubate for an additional 1 hour while rotating. To decrease nonspecific 
binding, the affinity beads were washed six times using same buffer. Bound proteins 
were eluted by boiling for 5 min in SDS-PAGE sample buffer, and a fraction was 
analyzed by 10% SDS-PAGE. Immunoblotting was performed using antibodies against 
ymIF2 (a generous gift from Dr. Gisela Kramer, the University of Texas at Austin) and 
commercially available anti-MBP (New England Biolabs). The western blots were 
visualized with enhanced chemiluminescence detection system (GE Healthcare).  
 
2.7 Plasmid constructs for Co-immunoprecipitation (Co-IP) assay 
To generate a pRS415-AEP3-HA construct, the wild-type AEP3 gene was 
isolated by PCR amplification using two primers: a forward primer 5’-
AGCCTCGAGCATAGCAGATTATACTA-3’ (A3-FOR; XhoI site is underlined) and 
5’- GGCGGATCCTCAAGCGTAGTCTGGGACGTCGTATGGGTAAACCTCCCCAAC- 
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TATTCTCCTCTTTAC-3’ (AP3-HA-Rev; BamHI site is underlined, stop codon is in 
bold. Italic letters are the HA epitope tag) (Figure 2.2). The resulting fragment from the 
PCR was purified (PCR purification kit, Qiagen), then digested with both XhoI and 
BamHI, gel-purified, and ligated into a pRS415 vector which was pre-cleaved by both 
restriction enzymes. The plasmid construct was isolated from E.coli XL1-B cells, and the 
sequence of the insert was verified at the DNA Core Facilities at the University of Texas 
at Austin.  
To generate the pRS415-AEP3-FLAG (Figure 2.3) or the c-Myc construct (Figure 
2.4), genomic AEP3 DNA was amplified by PCR using primers: A3-FOR (described 
above) and a reverse primer 5’-TTTCTAGAGTAATGGATCCAACCTCCCCAAC-3’ 
(XbaI and BamHI sites are underlined, respectively). The PCR product was purified 
(PCR purification kit, Qiagen), and digested with XhoI and XbaI. The gel-purified 
fragment was cloned into a pre-cleaved pRS415 vector to generate pRS415-AEP3-XbaI 
(Figure 2.5). After isolation of the plasmid construct from E.coli XL1-B cells, the 
construct was digested with BamHI and XbaI to make sticky ends at each side of the 
insert, which will allow the annealed primers to ligate into a pre-cleaved pRS415 vector. 
For the FLAG tagged construct, two different primers were used; 5’-
GATCCGACTACAAAGATGACGATGACAAGTAGT-3’ (FLAG-A3-BamHI; BamHI site 
is underlined. Stop codon is in bold. Italic letters are FLAG epitope tags) and 5’-
CTAGACTACTTGTCATCGTCATCTTTGTAGTCG -3’ (FLAG-A3-XbaI; XbaI site is 
underlined. Stop codon is in bold. Italic letters are complementary to FLAG epitope tags). 
Five μl of each primer (10 μM) was mixed with restriction enzyme buffers to give a total 
volume in 50 μl. The primer mixtures were boiled for 5 min, and cooled down at room 
temperature for 1 hour to anneal each other. Two μl of the annealed primer mixture was 
incubated with T4 polynucleotide kinase (Invitrogen, CA) to add an N-terminal 
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phosphate at 37oC for 1 hour, followed by another incubation at 65oC for 30 min. The 
annealed primers were diluted 1:20 in ligation buffer, and ligated into a pRS415-AEP3-
XbaI construct which was pre-cleaved with BamHI and XbaI. The sequence of the insert 
was verified by DNA sequencing.  
For the pRS415-AEP3-c-Myc construct, the same procedure was carried out 
described above except for using two different primers. 5’-
GATCCGAACAAAAACTCATCTCAGAAGAGGATCTGTGAT-3’ (cMyc-A3-BamHI; 
BamHI site is underlined. Stop codon is in bold. Italic letters are c-Myc epitope tags) and 
5’-CTAGATCACAGATCCTCTTCTGAGATGAGTTTTTGTTCG-3’ (cMyc-A3-XbaI; 
XbaI site is underlined. Stop codon is in bold. Italic letters are complementary to c-Myc 
epitope tags).  
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Figure 2.2:  Primers and amino acid sequence of the HA epitope-tagged AEP3     
construct. The stop codon is highlighted by red color. The HA tag is 
designated by pale blue color.  
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Figure 2.3:  Primers and amino acid sequence of the FLAG epitope-tagged AEP3 
construct 
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Figure 2.4:  Primers and amino acid sequence of the c-Myc epitope-tagged AEP3 
construct 
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Figure 2.5:  Overall scheme for construction of epitope-tagged AEP3 plasmids. The box 
represents how two primers containing the epitope-tag are designed to be 
annealed. 
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2.8 In vivo Co-immunoprecipitation (Co-IP) assay 
Cells containing HA-tagged AEP3 gene was used for co-immunoprecipitation 
(Co-IP) experiments. Yeast cells in 50 ml YPEG culture was harvested and washed twice 
with ice-cold water. Cells were resuspended in 500 μl of a co-ip buffer containing 50 mM 
Tris-HCl, pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM DTT, 10 mM MgCl2, and an 
aliquot of a cocktail of protease inhibitors (Hiley et al.) and were disrupted with glass 
beads using FastPrep FP120 cell disrupter (Qbiogene, CA). A cleared soluble lysate was 
obtained by centrifugation at 16,000 rpm for 30 min. Glass beads were washed in 500 μl 
of same buffer and centrifuged at 16,000 rpm for 30 min. Each pre-cleared soluble lysate 
was combined together. Pre-cleared lysate (1 ml) was then incubated with 10 μl of 
antibodies against HA epitope tags at 4oC for 4 hours while gently rotating. The mixture 
with anti-HA was incubated with 50 μl of Protein A sepharose beads (Invitrogen, CA) at 
4oC for overnight. Antibody-linked immunocomplexes were collected by centrifugation 
at 1,500 rpm for 2 min, washed five times in 500 μl of the co-ip buffer, and eluted from 
matrix with a SDS-PAGE sample buffer. Western blotting was performed to probe for 
HA-tagged AEP3 or ymIF2 using monoclonal HA anti-mouse antibody (Covance, CA) or 
ymIF2 polyclonal antibody (a generous gift from Dr. Gisela Kramer, the University of 
Texas at Austin) 
Two Co-IP controls were used: ∆aep3 yeast cells (strain DLY2) expressing on 
untagged AEP3 gene from a plasmid, and ∆ifm1 yeast cells (strain LOY1) expressing 
HA-tagged AEP3 gene from a plasmid.  
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Chapter 3:  Results and Discussion 
3.1 Identification of a mutation in a gene that causes the synthetic petite phenotype 
with the deletion of fmt1 
Deletion of the FMT1 gene is not essential for respiratory growth (Li et al., 2000). 
Therefore, we used this fact to design a genetic screening system to isolate mutations in 
the yeast genome that cause a synthetic petite phenotype (respiratory-deficient) with the 
deletion of the FMT1 gene. The strain with the deletion of the FMT1 gene was 
transformed with pRS416-FMT1, and then exposed to UV radiation to generate 
mutations (Protocol 8 in Appendix E). Cells were spread onto 200 complete 
nonfermentable carbon source medium plates (YPEG). This step eliminates mutations or 
petites which are not related to fmt1. By replica-plating onto 5-fluoroorotic acid 
contained plates (5-FOA), the URA3 borne pRS416-FMT1 plasmid was removed from 
the cells. Missing colonies on 200 new YPEG plates obtained by another replica-plating 
indicated that a mutation had occurred somewhere in the yeast genome and is 
synthetically petite with the deletion of fmt1. In other words, a gene containing a 
mutation is genetically interacting with the FMT1 gene. The genetic screen produced 8 
independent recessive nuclear mutations that caused synthetic petite phenotypes only 
when there is no formylation of initiator tRNA (only in the fmt1 deletion background).  
Among 8 synthetic petite mutant strains, one strain, synthetic petite (s.p.) mutant 
79-2, was chosen to search for the mutation by transformation with yeast genomic DNA 
library plasmids containing fragments of the complete genome of the wild-type yeast 
(Figure 3.1). The transformants were spread onto 100 minimal media-contained plates 
without uracil and leucine. By replica-plating onto 100 5FOA/YPEG plates, we isolated 
12 colonies that grew on the nonfermentable carbon source, indicating that each colony 
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has a gene that complemented the synthetic petite mutant phenotype. After rescuing 12 
DNA library plasmids from each colony, the DNA regions on the plasmids were 
sequenced (Experimental procedures 2.3), and analyzed by NCBI BLAST.  
 
3.1.1 Isolation of unknown ORF (open reading frame) on Chromosome XV  
The result of BLAST showed that one of the complementing plasmids contained 
the region in chromosome II where the FMT1 gene is located. All other eleven 
complementing plasmids contained common DNA regions on chromosome XV that 
overlapped with each other. The overlapping region was around 5kbp long, and included 
three verified genes and one unverified gene (Figure 3.2). The three genes are PET56 
(currently changed to MRM1), HIS3, and DED1 gene. To test which gene is responsible 
for the mutation causing the petite phenotype of s.p.79-2, each gene was isolated by 
restriction digestion of the plasmid using different enzymes, gel-purified, and inserted 
into a pre-cleaved pRS415 vector. Each construct was transformed into the s.p.79-2 
strain, and the resulting transformants were streaked onto a 5-FOA/YPEG plate (Figure 
3.3). The construct pRS415-HIS3, showing a respiratory-competent phenotype, contains 
both the HIS3 gene and the unknown ORF (unORF; YOR203W) that is downstream of 
the HIS3 gene (Figure 3.4). We realized that approximately 200bp in the middle of the 
HIS3 gene was already missing in the original yeast strain (Brachmann et al., 1998). 
Therefore, we deduced that the HIS3 gene could not be the candidate, and we focused on 
the unORF to test whether it is the gene complementing the phenotype of the s.p.79-2 
strain.  
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Figure 3.1:  Isolation of a mutant gene interacting with ∆fmt1. A red X mark   
represents the potential mutation site created by UV radiation 
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Figure 3.2:  Partial map of Chromosome XV containing overlapping DNA region from 
11 potential candidates. The blue open box represents an unknown     
open reading frame (unORF). Red arrows are verified genes.  
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Figure 3.3:  Complementation analysis on a 5-FOA/YPEG plate. Cells were grown at 
30oC for 6 days. Sectors (1), (2), and (3) were used as positive controls: (1) 
and (2) are from two of the 11 potential candidates. (3) Cells containing 
wild-type FMT1 plasmid. Sector (4) Cells containing a PET56 construct. 
Sector (5) Cells with the HIS3 construct. Sector (6) Cells with the DED1 
construct. 
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3.1.2 Characterization of unknown ORF on Chromosome XV 
The pRS415-HIS3 construct was digested with BamHI and HindIII to generate 
fragment which contains just the unORF region (Figure 3.4). It was gel-purified, and 
ligated into a pre-cleaved pRS415 vector to produce the pRS415-unORF construct. This 
construct was transformed into the s.p.79-2 strain to see whether it can complement the 
petite phenotype of this mutant strain. The pRS415-unORF construct complemented the 
petite phenotype of s.p.79-2 just as well as the pRS415-HIS3 construct in a spot dilution 
assay (Figure 3.5).  
Another method, the tetrazolium chloride (TTC) assay (Experimental procedures 
2.3.1), was used to test whether the pRS415-unORF construct is responsible for the 
complementation of the petite phenotype. The principle of the TTC assay is that the 
colorless chemical tetrazolium chloride diffuses into actively respiring cells, and it 
accepts electrons from the mitochondrial electron transport chain, reducing TTC to a pink 
compound, called formazan (Altman, 1976). The accumulation of this compound stains 
cells with a red color. S.p.79-2 cells expressing pRS415 empty vector (used as a negative 
control) were shown to have a white color. Cells expressing either the pRS415-HIS3 
construct or the pRS415-unORF construct were shown with red color, indicating that 
both constructs complemented the petite phenotype of s.p 79-2 strain (Figure 3.6).  
Table 3.1 summarizes the results of additional tests to confirm whether unORF is 
the gene that complements the petite phenotype of the s.p.79-2 strain. Further 
characterizations were hampered by inconsistent results that were obtained in different 
experiments, except that s.p.79-2 cells expressing pRS415-unORF always showed a 
positive result. At that point, we speculated whether the unORF is biologically active. 
One possibility was that unORF might express a functional protein. To test this 
possibility, site-directed mutagenesis was used to generate pRS415-SDM containing in 
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frame stop codons downstream of the AUG codon of unORF. If unORF encodes a 
functional protein, the pRS415-SDM construct could not complement the petite 
phenotype of s.p.79-2. However, this construct complemented the s.p.79-2 strain in both 
assays (Table 3.1). Also, we generated a construct containing the disruption of unORF 
region to investigate whether it is functional. The PstI restriction site is in the middle of 
unORF region. Therefore, the piece of unORF cut by both PstI and BamHI was cloned 
into a pRS415 vector to generate the pRS415-PstI construct (Figure 3.4). As shown in 
Table 3.1, this construct did not show reproducible results in both assays. Another 
possibility was that a high copy yeast expression vector containing unORF (PVT103L-
unORF) could complement s.p.79-2. The PVT103L-unORF construct also did not show 
reproducible results in two assays.  
Finally, we directly sequenced the region of Chromosome XV from s.p.79-2 and 
found no mutations in 5kbp long including PET56, HIS3, unORF and DED1 gene.   
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Figure 3.4:  Restriction sites map of pRS415-HIS3 construct. Yellow bar:               
original deletion part of the HIS3 gene. Red bar: the region of unORF. Pale 
blue bar: the HIS3 gene. Blue bar: the DED1 gene. pRS415-PstI contains the 
piece digested by PstI (2) and BamHI (B) enzymes. pRS415-unORF 
contains the piece digested by HindIII (4) and BamHI (B).  
 
 
 
 
 
UnORF
(A) 
(B)
(1) 
(2)
(3)
(4)
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Table 3.1: Summary of Inconsistent Results. Highlighted with yellow are inconsistent 
results. Y/N represents that the result was not reproducible.  
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Figure 3.5:  Spot dilution assay on a 5-FOA/YPEG plate. (1) Positive control, cells 
containing both the HIS3 gene and unORF. (2) Cells expressing the 
pRS415-unORF. (3) Cells containing a construct with a disruption of the 
unORF. The dilution is indicated at on the top of the figure.  
 
 
 
 
 
 
 
(3) 
(1) 
(2) 
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Figure 3.6:  Tetrazolium chloride (TTC) assay. Panel (1) Cells containing pRS415 
empty vector (Negative control). Panel (2) Cells with the pRS415-HIS3 
construct. Panel (3) Cells with the pRS415-unORF construct. Cells were 
grown on YPD plates at 30oC for 2 days, and then agar and TTC were 
overlaid. The plates were then incubated at room temperature for 3 hours.  
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3.1.3 Complementation groups analysis of the 8 synthetic petite mutant strains 
Despite our failure to identify the nature of the synthetic petite mutation in the 
s.p.79-2 strain, the fact that the pRS415-unORF construct consistently complemented the 
petite phenotype of the s.p.79-2 strain allowed us to use this construct for 
complementation group analysis of the 8 synthetic petite mutant strains isolated. pRS415-
unORF was transformed into the other 7 synthetic petite mutant strains. Table 3.2 
summarizes the complementation group analysis. Transformants were spread onto a 
minimal medium plate containing histidine and methionine. After colony purification, 
they were restreaked onto 5-FOA plates to evict pRS416-FMT1. The resulting colonies 
were tested for the petite phenotype using two different methods: growth on YPEG and 
tetrazolium chloride (TTC) assay (Figure 3.7).  
Only two mutant strains (s.p.175 and s.p.38) gave clear results in both assays, 
indicating that they represented different complementation groups from s.p.79-2.  
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Table 3.2: Summary of complementation analysis. Seven synthetic petite mutants were 
transformed with pRS415-unORF and tested for complementation of petite 
phenotype. Only s.p.175 and s.p.38 (highlighted by yellow) gave clear 
results in both assays, indicating different complementation groups from 
s.p.79-2.  
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Figure 3.7:   Isolation of complementation groups of synthetic petite mutants 
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3.2 Identification of a mutation in the AEP3 gene 
Based on complementation group analysis, the s.p.175 strain was used next to 
find a mutation in a gene that causes the synthetic petite phenotype in combination with 
deletion of the fmt1 gene. Transformation with a yeast genomic DNA library was done as 
described above (Result 3.1). Transformants were spread onto 70 minimal media plates 
without uracil and leucine, and then replica-plated onto 70 5-FOA/YPEG plates. Four 
potential candidates were obtained out of 6,000 colonies, screened, and retested by YPEG 
streaking (Figure 3.8). After rescuing the library plasmids from these 4 candidates, 
sequencing and BLAST analysis identified overlapping regions on chromosome XVI 
(Figure 3.9). This region contained 3 verified genes, and we immediately focused on the 
AEP3 gene, because the protein encoded by this gene is known to be a peripheral 
mitochondrial inner membrane protein (Ellis et al., 2004). 
To test whether AEP3 is responsible for complementation of the petite phenotype 
of the s.p.175 mutant strain, yeast genomic DNA was isolated from DAY4 cells and 
employed in PCR with specific primers to amplify the wild-type AEP3 gene. 
Subsequently, a pRS415-AEP3 construct was generated (Experimental procedures 2.3.2). 
After transformation into the s.p.175 mutant strain, it was confirmed that the AEP3 gene 
alone complemented the petite phenotype of the s.p.175 mutant strain (Figure 3.10).  
A mutation on the AEP3 gene created by UV radiation was subsequently 
identified by DNA sequencing. The AEP3 locus in the s.p.175 mutant strain was 
amplified by PCR using several different primers either sitting upstream of the start 
codon or in the middle of the AEP3 gene or downstream of the stop codon of the AEP3 
gene. The resulting PCR fragments were analyzed by DNA sequencing. A T at position 
913 of the AEP3 coding sequence was changed to A, as shown in the chromatogram of  
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the sequencing reaction (Figure 3.11). This mutation would cause a tyrosine to asparagine 
substitution at position 305 in the AEP3 protein (Y305N). 
We wanted to confirm the genetic interaction between AEP3 and FMT1. Based on 
the design of the screen, the aep3 mutation (Y305N) should only cause the petite 
phenotype in a ∆fmt1 background. An aep3 mutant construct (pRS415-AEP3-Y305N) 
was introduced into a yeast strain containing the wild-type FMT1, but the deletion of 
AEP3 (Figure 3.12). Cells containing pRS415-AEP3-Y305N grew on non-fermentable 
carbon sources medium, confirming that AEP3 genetically interacts with FMT1.  
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Figure 3.8:  Confirmation analysis of 4 potential candidates from the s.p.175 mutant 
strain. Colonies identified on YPEG plates containing DNA library plasmids 
were spread onto 5-FOA/YPEG plate at 30oC for 6 days. The four 
candidates, (1) – (4), are shown here. A DNA library plasmid rescued from 
(4) was transformed into s.p.79-2 (5). It did not complement the phenotype 
of s.p.79-2 mutant strain, indicating that the s.p.175 mutant strain is not in 
the same complementation group with the s.p.79-2 mutant strain.  
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Figure 3.9:  Partial map of Chromosome XVI containing overlapping DNA regions 
from 4 potential candidates to complement the phenotype of s.p.175 mutant 
strain. Red arrows are verified genes. The pink open box represents the 
AEP3 gene.  
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Figure 3.10: Complementation of the s.p.175 mutant strain with the pRS415-AEP3 
construct. Cells were grown at 30oC for 5 days on 5-FOA/YPEG plate. The 
bottom represents a negative control with the vector transformed into 
s.p.175 mutant strain. 
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Figure 3.11: DNA sequencing results verifying a mutation on AEP3 gene. The red   
boxes indicate the site of mutation.  
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Figure 3.12: Confirmation test of genetic analysis. Each strain was incubated at 30oC for 
5 days on YPEG medium.  
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3.3 Overexpression and purification of Aep3p 
The wild-type and Y305N AEP3 genes were isolated from strain DAY4 or 
s.p.175, respectively. The resulting PCR fragment was digested with restriction enzymes 
(Experimental procedures 2.4), gel-purified, and inserted into pRSET A vector 
(Invitrogen, CA) in such a way that it contained a hexahistidine tag fused upstream of the 
start codon. Induction with IPTG (Experimental procedures 2.4) produced insoluble 
AEP3 protein (Aep3p) at all different conditions tested. Therefore, we decided to express 
Aep3p as a fusion protein with the maltose-binding protein (MBP) using a pMALc2H10T 
vector (Experimental procedures 2.4). Immobilized Metal Affinity Chromatography 
(McCarthy and Brimacombe, 1994) with His·Bind matrix (Novagen) and Ni2+ as the 
ligand was used to purify the fusion protein (MBP-Aep3p). The purity of the recombinant 
fusion protein was as > 90% (Figure 3.13.A). The protein migrated at approximately 
110kDa which is consistent with the combined size of Aep3p plus MBP (Figure 3.13.A). 
The purification of a mutant protein was performed by the same procedure as described 
for the wild-type protein (Figure 3.13.B). 
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Figure 3.13: Analysis of purified MBP-Aep3p and MBP-Aep3p-Y305N by SDS-PAGE. 
Panel A. M: protein marker. Lane 1: soluble fraction after sonication. Lane 
2: Flow-through fraction. Lane 3: purified, dialyzed MBP-Aep3p fraction 
(15 μl; 63 pmol). Panel B. Lane 1: soluble fraction after sonication. Lane 2: 
purified, dialyzed MBP-Aep3p-Y305N fraction (5 pmol). Lane 3: purified, 
dialyzed MBP-Aep3p-Y305N fraction (40 pmol). The 10% gel was stained 
with Coomassie blue.  
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3.4 Binding of MBP-Aep3p to ymIF2 or its C2 subdomain  
The genetic interaction between AEP3 and FMT1 is observed under conditions 
where there is no formylation of mitochondrial initiator tRNA. We speculated that Aep3p 
might interact with factors that are involved in the initiation stage of protein synthesis. To 
date, the only initiation components that have been identified in yeast mitochondria are 
ymIF2 and the initiator tRNA. YmIF2 is responsible for binding and delivering the 
initiator tRNA to the 30S ribosome (Garofalo et al., 2003), and shows a 6 x preference 
for formylated versus unformylated Met-tRNAMet (Garofalo et al., 2003). Aep3p might 
interact with ymIF2 to stabilize initiator tRNA binding. Alternatively, Aep3p might 
interact directly with the initiator tRNA.  
To test whether Aep3p interacts with ymIF2, we used a MBP pull-down assay as 
described in Experimental procedures 2.6. Purified MBP-Aep3p and ymIF2 were 
incubated for 2 hours at room temperature. Complexes were isolated with amylose 
affinity beads and analyzed by SDS-PAGE and immunoblotting with antibodies against 
ymIF2. Figure 3.14 shows that ymIF2 is pulled down with MBP-Aep3p (lane 4), but not 
with MBP alone (lane 6).  
We also tested whether Aep3p binds to the C2 subdomain of ymIF2. The C2 
subdomain of ymIF2 is approximately 15kDa in molecular weight, and known as the 
binding site for initiator tRNA (Figure 3.15). Figure 3.15 shows that the C2 subdomain of 
ymIF2 binds to MBP-Aep3p (lane 7) about as well as the full-length ymIF2 (lane 4).   
These results could be obtained if Aep3p is simply a “sticky” protein, and binds to 
everything. Therefore, the binding of Aep3p to another protein was tested. The purified 
yeast cytosolic C1-THF synthase (Barlowe et al., 1989) was used as a negative control for 
the pull-down assay. The C1-THF synthase is approximately 100kDa in molecular weight 
and contains three functional activities in yeast cytoplasm (Appling and Rabinowitz, 
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1985). Purified C1-THF synthase was mixed with MBP-Aep3p, and the immunoblotting 
was performed using an antibody against C1-THF synthase. Lane 4 in Figure 3.16 shows 
that there was no C1-THF synthase in the pull-down fraction, indicating that Aep3p did 
not bind to cytosolic C1-THF synthase.  
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Figure 3.14: Aep3p binds to ymIF2 in vitro. Lane 1: protein marker. Lanes 2-4: binding 
test between Aep3p and YmIF2. Lane 2, unbound fraction. Lane 3, wash 
fraction. Lane 4: pull-down fraction. Lanes 5-6: binding test between MBP 
and ymIF2. Lane 5, unbound fraction. Lane 6, pull-down fraction. The 
immunoblotting was performed using an antibody against ymIF2. For lanes 
2-4, 40 pmol of each protein was used, and lanes 5-6, 20 pmol of each used.  
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Figure 3.15: Aep3p binds to the C2 subdomain of ymIF2. A. the domain structure of 
ymIF2 is shown. B. Lane 1: protein marker. Lanes 2-4: binding test between 
MBP-Aep3p and YmIF2. Lane 2, unbound fraction. Lane 3, wash fraction. 
Lane 4, pull-down fraction. Lanes 5-7: binding test between C2 subdomain 
and MBP-Aep3p. Lane 5, unbound fraction. Lane 6, wash fraction. Lane 7, 
pull-down fraction. The immunoblotting was performed using an antibody 
against ymIF2. For lanes 2-4, 20 pmol of each protein was used, and lanes 
5-7, 20 pmol of each used.  
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Figure 3.16: Aep3p does not bind to cytosolic C1-THF synthase. Lane 1: protein   
marker. Lanes 2-4: binding test between Aep3p and C1-THF synthase. Lane 
2, unbound fraction. Lane 3, wash fraction. Lane 4, pull-down fraction. The 
immunoblotting was done using an antibody against cytosolic C1-THF 
synthase. 20 pmol of each protein was used.  
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3.5 Binding of MBP-Aep3p to initiator tRNA  
To test whether Aep3p binds directly to initiator tRNA, we used the filter-binding 
assay as described (Experimental procedures 2.5). Various purified proteins were 
incubated with unformylated [35S]Met-tRNAMet or [14C]Lys-tRNALys (negative control). 
Figure 3.17 shows that Aep3p did not bind to any tRNA tested. YmIF2 binding to Met-
tRNAMetf  was used as a positive control (brown closed squares).  
 
3.6 The effect of Aep3p on the binding of ymIF2 to Met-tRNAMetf 
Although Aep3p did not bind directly to initiator tRNA (Figure 3.17), it did 
interact with ymIF2 in vitro (Figure 3.14). The filter-binding assay was used to test 
whether Aep3p affected the ymIF2-initiator tRNA binding. The gold diamonds show the 
binding of unformylated Met-tRNAMet by ymIF2 alone. MBP-Aep3p, added in equimolar 
amount with ymIF2, significantly stimulated the binding of Met-tRNAMet by ymIF2 (red 
circles) (Figure 3.18). MBP-Aep3p alone (green triangles) or MBP alone (blue inverted 
triangles) showed only background levels of tRNA binding. The point mutant of Aep3p 
(MBP-Aep3p-Y305N) was also tested in the filter binding assay. The mutant protein 
actually decreased the binding of Met-tRNAMet by ymIF2 (data not shown). This needs to 
be repeated after we solve the proteolytic degradation problem (Figure 3.13).  
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Figure 3.17: Aep3p does not bind to any tRNA. Each reaction is separately shown by 
color symbols and lines. Each assay was performed in duplicate. 
Nonspecific filter binding of each tRNA in the absence of proteins was 
subtracted. Data are expressed as means of two separate determinations ± 
S.E. 
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Figure 3.18: Aep3p promotes the binding of ymIF2 to Met-tRNAMetf. Each reaction is 
differently represented by colored symbols. Data are reported as means ± 
S.E., n = 2.  
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3.7 The binding assay of ymIF2 to Aep3p in vivo (Co-IP assay) 
To test whether Aep3p binds ymIF2 in vivo, we prepared an HA epitope-tagged 
version of AEP3 construct in a pRS415 vector (pRS415-AEP3-HA). This construct was 
transformed into a heterozygous diploid AEP3 strain (Y22823; Appendix C), sporulated, 
and dissected to obtain the strain ∆aep3 containing pRS415-AEP3-HA. We checked that 
the HA tag did not interfere with AEP3 function since cells containing pRS415-AEP3-
HA were grown on non-fermentable carbon sources (data not shown). Cells with this 
construct were grown in 50 ml YPEG media at 30oC for 2 days, followed by the Co-IP 
assay as described in Experimental procedures 2.8. As shown in Figure 3.19, we did not 
detect an interaction between Aep3p and ymIF2 in vivo (lane 4). For the control 
experiment, the pRS415-AEP3-HA construct was transformed into the strain ∆ifm1 
containing the pVT101U-bmIF2 construct (Appendix D). The Co-IP assay was 
performed as described above. We confirmed that several bands shown in lane 4 of 
Figure 3.19 were proteins unspecifically bound to antibodies against ymIF2 (data not 
shown).  
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Figure 3.19: The Co-IP assay. Lane 1: protein marker. Lane 2: unbound fractions. Lane 3: 
wash fractions. Lane 4: co-ip fractions.  
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3.8 DISCUSSION 
Formylation of the initiator Met-tRNAMetf is required for initiation of protein 
synthesis in bacteria (Sundari et al., 1976). Also, organelles such as chloroplast and 
mitochondria use formylated initiator Met-tRNAMetf for their protein synthesis 
(Bianchetti et al., 1971; Dickerman et al., 1967; Epler et al., 1970; Feldman and Mahler, 
1974; Galper and Darnell, 1969, 1971; Halbreich and Rabinowitz, 1971; Marcker and 
Sanger, 1964; Schwartz et al., 1967; Smith and Marcker, 1968). However, previous work 
in the Appling lab had demonstrated that the formylation of initiator Met-tRNAMetf is not 
necessary for mitochondrial respiration in S. cerevisiae (Li et al., 2000). Moreover, in 
vivo studies showed that protein synthesis in yeast mitochondria can be initiated under 
conditions where there is no formylation of initiator tRNA (Tibbetts et al., 2003). 
Therefore, we hypothesized that there might be additional factors that support the 
initiation process in yeast mitochondria. The fact that the FMT1 gene is not essential for 
mitochondrial protein synthesis or respiratory growth led us to design a genetic screening 
system to search for genes that are synthetically respiratory-deficient (petite) with 
deletion of the FMT1 gene. A mutation that causes synthetic petite phenotype in the 
absence of the FMT1 gene was found in the gene AEP3.  
Aep3p is a peripheral mitochondrial inner membrane protein. Aep3p is reported to 
stabilize the biscistronic transcript of the mitochondrially-encoded ATP6 and ATP8 
genes. The ATP6 and ATP8 genes encode the subunits of the ATP synthase. Ellis et al. 
(2004) investigated the nature of the aep3 mutant. Deletion of the AEP3 gene causes 
respiratory incompetence (petite phenotype). They also found that the aep3 mutant 
reduced levels of cytochrome b and cytochrome a+a3, and lacks oligomycin-sensitive 
ATPase activity. The decreased ATPase activity inspired them to determine whether it is 
the result of a loss of one or more of the mitochondrially-encoded subunits of ATP 
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synthase. In vivo labeling assay showed that subunit 9 (Atp9p) was not affected in the 
mutant strain, but both subunit 6 (Atp6p) and 8 (Atp8p) were almost undetectable. 
Therefore, they speculated that the lack of inhibition of the ATPase by oligomycin and 
the respiratory deficiency of the mutant strain resulted from the absence of both subunits. 
What these data suggested was that Aep3p may function to stabilize the transcript of 
ATP6 and ATP8. Northern analysis showed that the transcript levels of ATP8/6, which its 
transcript isolated from the aep3 mutant strain, were reduced by ~30% compared with 
that of the wild-type strain. Therefore, they concluded that the principal effect of the aep3 
mutation is on the stability of the ATP8/6 mRNAs (Ellis et al., 2004).  
However, one thing they ignored to point out was that the expression levels of 
other mitochondrially-encoded proteins in the aep3 mutant strain were also reduced 
(Figure 3 of Ellis et al., 2004). This fact led us to hypothesize that Aep3p also may 
function in the mitochondrial protein synthesis. To date, no studies have been reported 
whether the AEP3 is involved in initiation of protein synthesis in yeast mitochondria. Our 
genetic screening results suggest that the AEP3 gene product in the absence of the FMT1 
gene product, the methionyl-tRNA formyltransferase, is involved in initiation process, 
raising the possibility of AEP3-interaction with components of the protein synthesis in 
yeast mitochondria.  
Initiation factor 1, 2, and 3 (IF1, IF2, and IF3) take part in the assembly of 
initiation complexes including initiator fMet-tRNAMetf in bacteria (Laursen et al., 2005). 
In mitochondria, the initiation of protein synthesis should be similar to the bacterial 
process as is believed so far. To investigate the initiation of protein synthesis in yeast 
mitochondria in regard to whether or not AEP3 is associated with the initiation process, 
we focused on yeast mitochondrial IF2 (ymIF2) that is the only factor which has been 
identified and characterized (Garofalo et al., 2003). Bacterial IF2 and S. cerevisiae ymIF2 
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are apparent homologs. However, there is no obvious homolog between bacterial IF1 or 
IF3 and yeast mitochondrial initiation factors.  
The discovery that Aep3p binds to ymIF2, especially to its C2 subdomain raised 
the possibility for the association of Aep3p with initiator tRNA. However, Aep3p did not 
bind to any tRNA tested in this assay including Lys-tRNALys as a negative control 
(Figure 3.17). Although Aep3p does not directly bind the initiator tRNA, the binding 
between Aep3p and ymIF2 left open the possibility that Aep3p could affect the 
interaction of ymIF2 with initiator tRNAs. Indeed, Aep3p promoted the binding of ymIF2 
to unformylated initiator tRNA (Met-tRNAMetf) (Figure 3.18).  
Although we have seen the binding of Aep3p to ymIF2 in vitro, we could not 
detect any interaction between them in vivo (Figure 3.19). The one possibility to explain 
why the in vivo assay did not work is that the expression level of ymIF2 is very low in 
yeast cells. The Appling lab unsuccessfully tried to detect ymIF2 in the yeast cells or in 
mitochondria using the same antibodies. However, when they cloned the wild-type IFM1 
gene into a pVT101U, a high copy yeast expression vector (Appendix D), and 
transformed it into the ∆ifm1 strain, they found that the construct complemented the 
respiratory defect and ymIF2 expressed on the construct was detected by the same 
antibodies against ymIF2 (unpublished data).  
Few other “factors” involved in initiation of protein synthesis in S. cerevisiae 
mitochondria have been characterized. A recent study showed that the RSM28 gene 
encoding the mitochondrial small ribosomal protein Rsm28p genetically interacts with 
the IFM1 gene encoding ymIF2 and the FMT1 gene encoding the methionyl-tRNA 
formyltransferase in S. cerevisiae (Williams et al., 2007). Although Rsm28p does not 
appear to be a homolog of bacterial IF1 or IF3, its interaction with the IFM1 and the 
FMT1 suggests a role in the initiation process in yeast mitochondria. Our own genetic 
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and biochemical analyses suggest that Aep3p is also associated with the initiation 
process. AEP3 was discovered under conditions where there is no formylation of initiator 
tRNA. Therefore, we propose a model in which Aep3p binds to ymIF2 causing a 
structural change of ymIF2. This change facilitates the binding of unformylated initiator 
tRNA. In vitro, ymIF2 shows a binding preference for fMet-tRNAMetf over Met-tRNAMetf 
(Garofalo et al., 2005). Because Aep3p did not affect the binding of ymIF2 to fMet-
tRNAMetf (preliminary data), Aep3p function may become critical for unformylated Met-
tRNAMetf in the mitochondria, perhaps increasing the affinity between ymIF2 and Met-
tRNAMetf.  
Aep3p is not a homolog of bacterial IF1 or IF3 or mammalian IF3. However, the 
discovery of Aep3p gives more insights into the mechanism by which the initiation 
process of protein synthesis in yeast mitochondria occurs under conditions where there is 
no formylated initiator tRNA, and may open more possibilities for higher eukaryotes to 
follow the same mechanism when cells encounter in special situations.  
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PART II 
Chapter 4:  Introduction 
Transfer RNA from all species contains various modifications on the four 
canonical nucleosides: adenosine (A), guanosine (G), uridine (U), and cytidine (C). There 
are more than 100 different post-transcriptional modifications characterized in tRNAs 
across archaea, bacteria, and eukaryotes (Rozenski et al., 1999). In particular, the position 
37 (3’ to the anticodon) contains one of the largest variety of modifications (Bjork et al., 
2001), and that modification is often 1-methylguanosine (m1G) (Figure 4.1). This m1G37 
modification is one of the most ancient tRNA modifications present in all organisms as 
well as mitochondria.  
Many studies have reported on the effect of m1G37 modification. This 
modification is important to prevent translational frameshifting (Bjork et al., 1989). The 
authors generated a temperature-sensitive mutant gene (trmD3) for the m1G modification 
in the three proline tRNA species of Salmonella typhimurium. When grown at high 
temperatures, all proline tRNAs from the mutant strain were almost devoid of m1G, and 
the cells exhibited high levels of frameshifting. Hagervall, et al. (1990) studied the 
functional aspect of the m1G37 modification of tRNA in Salmonella typhimurium. They 
observed that the presence of m1G improved the rate of cellular growth and the absence 
of m1G reduced the rate of polypeptide elongation. They also found that m1G prevented 
the tRNA from frameshifting (Hagervall et al., 1990).  
Other reports also demonstrated that the m1G37 modification improved the 
reading frame maintenance. Urbonavicius, et al. (2001 and 2003) tested whether m1G37 
modification affects the frameshifting. They used an assay system to measure +1 
frameshifting. For this assay, the β-galactosidase activity was used to measure the 
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frequency of frameshifting. They found that m1G37 modification improved the reading 
frame maintenance by preventing +1 frameshifting errors. In addition, these authors also 
tested whether m1G37 influences reading frame maintenance by affecting -1 
frameshifting. Interestingly, they found that m1G37 modification did not influence or 
only slightly increased the frequency of -1 frameshifting. Therefore, they concluded that 
while m1G at position 37 has a profound influence on preventing +1 frameshifting, it has 
little effect on -1 frameshifting errors (Urbonavicius et al., 2001; Urbonavicius et al., 
2003).  
Putz, et al. (1994) showed that the m1G37 modification played an important role 
in the fidelity of tRNA aminoacylation. They found that m1G37 prevented the 
mischarging of yeast tRNAAsp by arginyl-tRNA synthetase (ArgRS). The kinetic analysis 
indicated that the efficiency of arginylation on tRNAAsp with m1G37 modification was 
reduced around 400-fold as compared with unmodified tRNA, indicating that the m1G37 
modification was responsible for the discrimination by ArgRS against tRNAAsp, and was 
the strong anti-determinant preventing efficient tRNAAsp mischarging by yeast ArgRS 
(Putz et al., 1994).  
Li, et al. (1997) also tested whether tRNAs (Leu-tRNALeu, Pro-tRNAPro, and Arg-
tRNAArg) isolated from a mutant strain (trmD3) of Salmonella typhimurium show the 
deficiency of m1G37 modification, and this deficiency affects the rate of aminoacyl-
tRNA (aa-tRNA) selection. They used an assay called “speedometer” to determine the 
relative rate of the first step in the translation elongation cycle. If an aminoacyl-tRNA 
binds successfully to its test codon, no β-galactosidase is synthesized due to the absence 
of frameshifting. If it unsuccessfully binds to the test codon due to the frameshifting, it 
activates the β-galactosidase. Based on relative β-galactosidase activity, they determined 
the intrinsic rate (rate of the aa-tRNA/rate of the frameshift) in a trmD3 mutant relative to 
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the wild-type. They found that m1G37 strongly stimulated the selection rate of the three 
tRNA species specific for proline, and one tRNA species specific for arginine. Also, they 
showed that mutant tRNAs slowed aminoacyl-tRNA selection at the ribosome. Therefore, 
they concluded that the m1G37 modification affects in vivo the aminoacyl-tRNA 
selection (Li et al., 1997).  
 
4.1 The tRNA (m1G37) methyltransferase 
The enzyme, tRNA (guanine-N1-)-methyltransferase, is responsible for the 
methylation on position 37 of tRNA. In bacteria, trmD encodes this enzyme, and in 
archaea or eukaryotes, TRM5 encodes the enzyme (Bjork et al., 2001; Christian et al., 
2004; Sindhuphak et al., 1985). The bacterial trmD is composed of two domains. The N-
terminal domain is known as the binding site for the AdoMet cofactor. The C-terminal 
domain binds the target tRNA. There is a flexible linker between two domains (Malone et 
al., 1995; Martin and McMillan, 2002; Schluckebier et al., 1995). When TrmD in E.coli 
or TRM5 in yeast is disrupted, mutant cells showed a severe growth defect, indicating that 
m1G modification of tRNA is important (Bjork et al., 2001).  
The bacterial TrmDs are quite similar, sharing 33% identity and 75% similarity 
among themselves (Li and Bjork, 1999). Surprisingly, the E.coli trmD gene and yeast S. 
cerevisiae TRM5 gene are not homologous to each other, sharing only 18% identity and 
45% similarity (Bjork et al., 2001). Even the TRM5 gene, which is responsible for the 
m1G modification in archaeal tRNA, appears not to be a homolog of the E.coli trmD gene 
(Hou et al., 2006). Therefore, m1G modifying enzymes may have evolved twice.  
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4.2 The purpose of present study 
In S. cerevisiae, at least eight cytoplasmic tRNAs are methylated at guanosine 37 
catalyzed by the TRM5 protein (Trm5p) (Bjork et al., 2001; Hiley et al., 2005). Trm5p 
catalyzes the transfer of the methyl group of AdoMet to the N1 of guanosine in position 
37 in those tRNAs. In eukaryotic cells, the modification of nucleotides in tRNAs occurs 
in the nucleus, and continues further in the cytoplasm. If those tRNAs contain an intron, 
an additional maturation step must take place for the removal of the intron before tRNAs 
are transported to the cytoplasm. The enzymatic formation for the m1G modification is 
hindered by an intron (Grosjean et al., 1997). Therefore, this modification takes place 
only after intron removal (Johnson and Abelson, 1983; Nishikura and De Robertis, 1981). 
For example, in yeast tRNAPhe, the enzymatic formation of m1G37 was completely 
hindered by a naturally occurring intron (Jiang et al., 1997). The m1G37 modification is 
the first obligatory intermediate of yW37 (nucleoside of the Y-base) synthesis, and tRNA 
(guanine-N1-)-methyltransferase also participates in the synthesis of yW37. Therefore, 
all the enzymes required for yW37 synthesis, including the tRNA (guanine-N1-)-
methyltransferase, are cytoplasmic (Droogmans and Grosjean, 1987).  
In yeast mitochondria, at least eight tRNAs, including the initiator tRNA (Figure 
4.2) and tRNAPhe are also methylated at guanosine position 37 (Canaday et al., 1980; 
Dunin-Horkawicz et al., 2006; Martin et al., 1978). However, the enzyme responsible for 
the methylation of mitochondrial tRNAs has not been identified (Figure 4.3). It has been 
proposed that nuclear-encoded Trm5p might be transported into mitochondria and be 
responsible for the methylation of mitochondrial tRNAs (Bjork et al., 2001; Brule et al., 
2004). A potential mitochondrial targeting signal (MTS) exists at the N-terminal end of 
Trm5p, but only cytoplasmic and nuclear localization of Trm5p has been reported (Huh 
et al., 2003). 
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In the present study, genetic and biochemical analyses are used to answer these 
open questions. First, is Trm5p localized to both the cytoplasm and the mitochondrial 
matrix? Second, can Trm5p methylate guanosine at position 37 of mitochondrial tRNAs, 
especially initiator tRNA and tRNAPhe? Third, is the product generated by Trm5p m1G? 
Also, the mechanism by which the TRM5 gene encodes a protein for dual localization and 
how the methylation of mitochondrial tRNAs affects on mitochondrial protein synthesis 
in S. cerevisiae are described.  
Portions of this study have been published in the Journal of Biological Chemistry 
(Lee, C., Kramer, G., Graham, D.E., and Appling, D.R. 2007 J. Biol. Chem. 282, 27744-
27753). These sections are identifiable by quotation marks.  
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Figure 4.1:  The structure of 1-Methylguanosine (m1G). The methyl group is highlighted 
by a red open box  
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Figure 4.2:  Secondary structure of mitochondrial initiator tRNA in S. cerevisiae. The 
m1G37 modification is highlighted by a red box.  
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Figure 4.3: Overall view of m1G modification on tRNAs by Trm5p 
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Chapter 5:  Experimental procedures 
The experimental methods used to study the TRM5 gene in Saccharomyces 
cerevisiae are described in the following sections. Yeast strains and plasmids used for 
this work are summarized in Appendix C and D. 
 
5.1 Chemicals, reagents, and strains 
Chemicals and biochemicals, of the highest grade commercially available, were 
obtained from Sigma (St. Louis, MO), Fisher Scientific (Fair Lawn, NJ), or VWR (West 
Chester, PA) and used without further purification. Geneticin (G-418 sulfate) was 
purchased from American Bioanalytical (Natick, MA). From Ambion (Austin, TX), RPA 
III ribonuclease protection assay kit, RNA marker templates, and SUPERase-in were 
obtained. The commercially produced enzymes such as ribonuclease P1, 
phosphodiesterase I, bacterial alkaline phosphatase, T7 RNA polymerase Plus, Moloney 
murine leukemia virus reverse transcriptase, T4 DNA ligase, T4 polynucleotide kinase, 
KOD Hot Start DNA polymerase, and proteinase K were purchased from Sigma, 
Worthington, Fermentas, Ambion, Ambion, Epicenture, New England Biolabs, Novagen, 
and Fisher Biotech, respectively. [γ-32P]ATP (PerkinElmer Life Sciences, Waltham, MA) 
and [methyl-3H]S-adenosyl-L-methionine (PerkinElmer Life Sciences or MP 
Biomedicals) were purchased. From Sigma, Saccharomyces cerevisiae total tRNA (Type 
X) was obtained. Artificially synthesized oligonucleotide primers were purchased either 
from Bio-Synthesis (Lewisville, TX) or from Sigma-Genosys or Integrated DNA 
Technologies (Corallville, IA). Antibodies against GFP were obtained from AnaSpec 
(San Jose, CA). Dr. John Tesmer (University of Michigan) kindly gave us both the 
Escherichia coli expression vectors pMALc2H10T (Kristelly et al., 2004) and pRK793 
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(Kapust et al., 2001). DNA sequencing for recombinant plasmids with inserts was done at 
the DNA Core Facilities of the Institute for Cellular and Molecular Biology at The 
University of Texas at Austin.  
E.coli Rossetta 2 (DE3) (Novagen) and E.coli JM109 (Promega) were grown 
aerobically in Luria-Bertani medium at 37oC. The S.cerevisiae strains used in this work 
are summarized in Appendix C. Yeast media, YPD (1% yeast extract, 2% Bacto-peptone, 
and 2% glucose), YPEG (1% yeast extract, 2% Bacto-peptone, 2% ethanol, and 3% 
glycerol) , and YMD (0.7% yeast nitrogen base without amino acids and 2% glucose 
supplemented with the following nutrients as indicated (final concentration in mg/L): 20-
histidine, 30-leucine, 30-lysine, 20-methionine, and 20-uracil) were used to grow yeast 
cells (Tibbetts et al., 2003).  
To isolate yeast genomic DNA, DAY4 cells were used. Haploid ∆trm5 cells 
(DLY1) were obtained from Y21898 (Appendix C) by sporulation and tetrad dissection 
(Chan and Appling, 2003). The plasmid constructs used in this study are summarized in 
Appendix D.  
 
5.2 Preparation of yeast mitochondria 
Mitochondria were isolated by spheroplasting and differential centrifugation as 
described (Daum et al., 1982). Yeast cells were grown aerobically in 1L of semisynthetic 
galactose media containing 3 g of yeast extract, 10 g of galactose, 0.8 g of (NH4)2SO4, 
0.7 g of MgSO4· 7H2O, 0.5 g of NaCl, 1 g of KH2PO4, 0.4 g of CaCl2, and 5 mg of 
FeCl3·6H2O. Cells were harvested at mid-log phase and converted to spheroplasts using 
lyticase (Sigma, St.Louis, MO). Spheroplasts were resuspended in a buffer, and then they 
were homogenized using a tight-fitting dounce homogenizer with 15 strokes. Cell debris 
was pelleted by centrifugation at 4,000 x g. After one more centrifugation, the 
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supernatant was collected and centrifugated at 15,000 x g for 30 min. The mitochondria 
were resuspended and stored in aliquots at -70oC. The final concentration of the isolated 
mitochondria was determined by the Bradford protein assay (Bradford, 1976).  
 
5.3 Cloning of yeast TRM5 for protein expression in E.coli and purification of MBP-
Trm5p 
The yeast genomic DNA was used to isolate the wild-type TRM5 (YHR070w) 
ORF by PCR. The primers used: TRM5-F 5’-
GGTCTAGAATGAAAATCGCACTGCCAGT-3’ (forward; restriction site XbaI is 
underlined; start codon is in bold) and TRM5-R 5’-
GGAAGCTTCATACGTTAGCTGGAAGTTGG-3’ (reverse; restriction site HindIII is 
underlined; stop codon is in bold). The obtained PCR products were digested with the 
same restriction enzymes, ligated into the same sites of the digested vector pMALc2H10T. 
The plasmid was transformed into E.coli JM109 cell. The recombinant construct was 
introduced by transformation into E.coli Rosetta2 (DE3) cells to express the TRM5 
protein as a fusion protein (MBP-Trm5p) containing the maltose-binding protein (MBP) 
and decahistidine tag. Heterologous protein was expressed in these cells after induction 
with 0.5mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 29oC for three hours. The 
cells were harvested, washed and kept at -80oC.   
Cells from a 2-liter culture of E.coli expressing MBP-Trm5 were used and lysed 
by sonication in 15 ml of binding buffer containing benzamidine (1 mM) and 
phenylmethanesulfonyl chloride (PMSF, 1 mM) as protease inhibitors. After 
centrifugation at 16,000 rpm for 20 min, the supernatant was loaded onto a His-bind 
matrix which has a 5 ml-bed volume and was equilibrated in 1 X binding buffer 
containing 5 mM imidazole in 20 mM Tris-HCl buffer, pH 7.8. After washing, loosely 
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bound protein was eluted with wash buffer containing 60 mM imidazole and 500 mM 
NaCl in Tris buffer, and tightly bound protein was eluted with 250 mM imidazole in the 
same Tris/NaCl buffer. The protein fractions eluted by 250 mM imidazole were dialyzed 
in 500ml of 20mM Tris-HCl, pH 7.5 for four hours. The dialyzed proteins were stored in 
– 80oC.  
 
5.4 Subcellular fractionation of mitochondria and immunoblotting against GFP 
Mitochondria were isolated as described in section 5.2. The commercially 
available strain EY0986/TRM5-GFP was used for isolation. After differential 
centrifugation, the post-mitochondrial supernatant was used as the cytoplasmic fraction. 
Each fraction containing 70 μg of mitochondria were loaded onto a 10% SDS-PAGE gel 
(Laemmli, 1970), and immunoblotted as described (Prasannan et al., 2003) using anti-
GFP as primary antibodies in a 1:500 dilution or anti-Hsp60 antibodies in a 1:50,000 
dilution. About 50 μg of mitochondria were resuspended in 100 μl of isotonic buffer 
containing 0.6 M sorbitol and 20 mM HEPES-KOH, pH 7.4. The 5 μl of proteinase K at 
1 mg/ml was added to the mitochondria samples and incubated for 15 min on ice. After 
10 min of proteinase K treatment, in some digestions, Triton X-100 having a final 
concentration of 0.5% was added to the mitochondrial samples to solubilize membranes. 
Digestions were stopped by addition of 1 μl of 100 mM phenylmethylsulfonyl fluoride in 
ethanol, and incubated for 10 minutes on ice. After centrifugation at 12,000 x g for 15 
min, mitochondria were collected and resuspended in SDS sample buffer. Each sample 
was loaded onto a 7.5% SDS-PAGE gel, and protein was analyzed by immunoblotting as 
described above.   
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5.5 TRM5 Transcript mapping using 5’- RACE experiment 
A 5'-RACE (RNA ligase-mediated rapid amplification of cDNA ends) experiment 
that is designed as a primer extension-based method was used to identify the 
transcriptional start sites for the TRM5 gene using the FirstChoice RNA ligase-mediated 
RACE kit from Ambion. Total RNA was isolated from the yeast strain DAY4 (Appendix 
C) using the RNeasy Mini Kit (Qiagen). To eliminate DNA contamination of total RNA, 
a Turbo DNA-free kit from Ambion was used. The four primers were used for this 
experiment. Two of them were provided by the kit as two nested 5’-RACE primers. The 
other ones were designed to be specific to the TRM5 transcript. The TRM5-specific inner 
primer 5’- ACTAAGCTTCACACTGATATTTTTGGGTTCGG-3’ (5R_AGA_IP; the 
restriction site BamHI is underlined) was complementary to nucleotides +183 to +161. 
The TRM5-specific outer primer 5’- GTACACTTGTCAGTTCGTCC -3’ 
(5R_AGA_OP) was complementary to nucleotides +283 to +264. The 5’-RACE inner 
primer and the TRM5-specific inner primer had BamHI and HindIII restriction sites, 
respectively, at their 5’ ends to facilitate cloning. PCR fragments created by “inner 
primers” were cloned into a pBluescript II KS(+/-) vector (Stratagene, La Jolla, CA) 
(Prasannan et al., 2003) and sequenced at the DNA Core Facilities at The University of 
Texas at Austin.  
 
5.6 Construction of TRM5 Truncation mutants and their expression in yeast 
To construct the wild-type TRM5 gene in a plasmid, yeast genomic DNA obtained 
from DAY4 strain was amplified by PCR using KOD Hot Start DNA polymerase and 
two primers; 5’- AGTGAAGCTTCCCTGTGTTGTTATAG – 3’ (TRM5_FOR; the 
BamHI site is underlined) and 5’- AGCTGGATCCGCCTTTTTGCCTTT - 3’ 
(TRM_REV; the HindIII site is underlined). The resulting PCR fragment was gel-
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purified, digested with same enzymes, and ligated into a pRS416 vector and a pRS415 
vector to produce the pRS416-TRM5 and pRS415-TRM5 wild-type constructs, 
respectively. Both pRS416 and pRS415 vectors (Sikorski and Hieter, 1989) (Appendix 
D) are yeast low-copy vectors containing the URA3 gene and the LEU2 gene as markers 
respectively.  
To generate the construct with codons 1-19 of the TRM5 coding sequence deleted, 
sequence and ligation-independent cloning (SLIC) was used (Li and Elledge, 2007). The 
four different primers were used for this methods: T7 forward primer 5’-
AATACGACTCACTATAGGG-3’ versus T5_1/20_2 reverse primer 5’-
CACTGGTGACATGCAATGAAAAATATCCTT-3’ (stop codon is in bold) and 
T5_1/20_3 forward primer 5’- 
AGGATATTTTTCATTGCATGTCAGGAGTGTTCCCA-3’ (start codon is in bold) 
versus T3 reverse primer 5’- AATTAACCCTCACTAAAGGG -3’. Two PCR fragments 
obtained from each PCR reaction, and the pRS415 vectors which were linerized with 
both BamHI and HindIII enzymes were gel-purified and treated with T4 DNA 
polymerase to generate 5’ overhang at each end. The two PCR products and the 
linearized vector were annealed at a 2:2:1 molar ratio with 20 ng of RecA protein at room 
temperature for 30 min, and the reconstructed plasmid (pRS415-∆1-19TRM5; Appendix 
D) was obtained from transformed E.coli XL1-Blue cells.  
The Splice Overlap Extension (SOE) PCR method (Horton et al., 1993) was 
introduced for generating mutant constructs with codons 1-33 deleted (pRS415-∆1-
33TRM5; Appendix D) and 1-47 deleted (pRS415-∆1-47TRM5; Appendix D). For the 
pRS415-∆1-33TRM5 construct, the TRM5 gene containing 300 bp of 5’-UTR in the 
pRS416-TRM5 plasmid was amplified with the T7 forward primer (upstream vector 
primer) and T5_1/34_2 5’-TTCTCGCATGCAATGAAAAATATCCTT-3’ (stop codon 
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is in bold). The DNA in the region between codon 34 and the stop codon of TRM5 was 
amplified by PCR using primers T5_1/34_3 5’-
TTTCATTGCATGCGAGAATTGGATAGG-3’ (start codon is in bold) and T3 reverse 
primer 5’-AATTAACCCTCACTAAAGGG-3’ (downstream vector primer). Primers 
T5_1/34_2 and T5_1/34_3 contain complementary nucleotides of 18 base pairs at their 
5’ends for the second SOE PCR. Two separate reactions obtained from PCR were 
purified by a PCR purification kit (Qiagen, Germany) and mixed together for the second 
PCR using the T7 forward primer and the T3 reverse primer. The resulting PCR product 
was gel-purified, digested with HindIII and BamHI, and cloned into a pRS415 vector 
(Sikorski and Hieter, 1989). The pRS415-∆1-47TRM5 construct was similarly generated 
using the T7 forward primer and T5_1/48_2 5’-
TGCACACATGCAATGAAAAATATCCTT-3’ (stop codon is in bold). T5_1/48_3 5’-
TTTCATTGCATGTGTGCAGTCAAGTTC-3’ (start codon is in bold) and T3 reverse 
primer were used to generate a product for the first PCR. T5_1/48_2 and T5_1/48_3 
contain 18 base pairs of complementarity at their 5’ ends for the second SOE PCR. The 
procedure described above was used for the second PCR, and then cloned into the 
pRS415 vector. All truncation mutant constructs were DNA-sequenced at the DNA Core 
Facilities at The University of Texas at Austin, and they were transformed into the DLY1 
strain containing pRS416-TRM5 for subsequent analysis.  
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5.7 Oxygen consumption assay 
To measure the oxygen consumption rates of cells containing either pRS415-
TRM5, pRS416-TRM5, pRS415-∆1-19TRM5, or pRS415-∆1-33TRM5, an oxygen 
consumption assay was used. A standard Clark-type electrode (model 5300A; YSI Inc.) 
was inserted into the airtight chambers containing the cells and oxygen consumption was 
measured at 30oC for at least 10min. Rates (nmol oxygen min-1) were normalized to the 
OD600 of each culture.  
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Chapter 6:  Results and Discussion 
6.1 Expression of Trm5p as a fusion protein 
Several attempts to express Saccharomyces cerevisiae Trm5p in different E.coli 
expression systems fused to N- or C-terminal polyhistidine tags produced mostly an 
insoluble form of the protein. Therefore, the full-length TRM5 ORF containing codons 
for 499 amino acids was cloned into the vector pMALc2H10T to express the N-terminal 
maltose-binding protein, a decahistidine tag, and the tobacco etch virus (TEV) protease 
cleavage site just upstream of the coding sequence for Trm5p (MBP-Trm5; Figure 6.1). 
E.coli cells expressed this fusion protein at high levels in soluble form. Nickel affinity 
chromatography was used to purify this fusion protein, and almost pure fusion protein 
(>95% in purity) was obtained. The mass of this fusion protein when analyzed by SDS-
PAGE was around 97kDa which is very similar to the calculated mass of 101.4kDa.  
 
6.2 Methyltransferase activity of the MBP-Trm5 fusion protein and its cleavage 
product (performed by Dr. Gisela Kramer) 
To separate Trm5p from MBP, the tobacco etch virus protease site was cleaved by 
its protease. The Trm5p fragment migrated on an SDS-PAGE gel with an apparent mass 
of 61 kDa, very close to its predicted mass of 57.2 kDa. The MBP fragment showed a 
band on the gel around 42 kDa which is similar to its predicted mass of 44.2 kDa. The 
fusion protein showed substantial methyltransferase activity in assay when ∆trm5 tRNA 
was used as substrate (Table 6.1).  
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Figure 6.1:   The Map of MBP-Trm5p. 
 
 
 
 
 
TRM5
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Table 6.1:   Test of Enzymatic activity for MBP-Trm5 
This table has been published as supplementary table 2 in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753. 
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However, when MBP-Trm5p was preincubated with buffer alone or tobacco etch 
virus protease, methyltransferase activity was considerably reduced. This could be due to 
inherent instability of the enzyme. Therefore, all subsequent experiments described here 
were carried out with the uncleaved fusion protein (MBP-Trm5p). Maltose-binding 
protein (MBP) was purified from empty pMALc2H10T vector in order to use it as a 
control for methyltransferase assay experiment. The MBP did not show any activity when 
incubated with ∆trm5 tRNA and AdoMet (data not shown).  
When a saturating amount of MBP-Trm5p and 50μM [3H]AdoMet were used in 
the assay, a linear relationship was observed between the amount of ∆trm5 tRNA 
substrate and the incorporation of methyl groups (Figure 6.2A). A specific enzymatic 
activity of 30 ± 1.3 nmol of methyl incorporated per min per mg MBP-Trm5p was 
calculated when a small amount of enzyme and saturating amount of substrates were used 
at initial rate conditions. The fusion protein did not catalyze the methylation of wild-type 
yeast total tRNA probably due to full methylation of tRNA.  
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Figure 6.2:  MBP-Trm5 methyltransferase activity. A, trm5 tRNA as substrate. The 
methyltransferase assay was carried out as described under "Experimental 
Procedures" with 0.8 µg of MBP-Trm5 enzyme, 50 µM [methyl-
3H]AdoMet, and trm5 tRNA. B, synthetic tRNAMetf as substrate. 
Synthetic tRNAMetf was heated at 70 °C for 5 min, and then cooled to room 
temperature immediately before the reaction mixtures were assembled. The 
reactions contained 0.8 µg of MBP-Trm5 enzyme and the indicated amount 
of the tRNAMetf in the standard assay. The results from duplicate reactions 
are shown fit to a linear model (R2 = 0.98). This figure has been published 
as figure 1 in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753.  
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6.3 Identification of the TRM5 tRNA methylation site and product (performed by 
Dr. Gisela Kramer and Dr. David E. Graham) 
To demonstrate that the MBP-Trm5 protein catalyzed the methylation of 
guanosine position 37 of tRNAs, on N1 position of the guanine base, primer extension 
assay was used (Jackman et al., 2003). The methylation of N1 position of guanine base 
interferes with Watson-Crick base pairing. Therefore, the reverse transcriptase cannot 
incorporate a complementary cytidylate, resulting in blocking further primer extension. 
Two different [32P] labeled oligonucleotide primers that are specific for yeast 
mitochondrial tRNAs such as the initiator tRNA and mitochondrial Phe-tRNAPhe were 
used. Phe-tRNAPhe also in its native form has an m1G37 modification following A36 
(Martin et al., 1978). Total tRNAs obtained from cells expressing wild-type or ∆trm5 
were annealed to primers, and then the reverse transcriptase reaction was carried out. The 
primer extended samples were analyzed by denaturing gel electrophoresis (Figure 6.3). 
The reverse transcriptase extended the primers up to m1G37 in the wild-type tRNAs, 
terminating the reaction at position 38 which is opposite the A (Figure 6.3; Lanes 1 and 
4). In contrast, reactions containing undermodified ∆trm5 tRNA showed that there is the 
presence of the full-length transcripts (Figure 6.3; Lanes 3 and 6). Lanes 2 and 5 showed 
that a significant amount of the transcripts were observed on the gel where the 
termination position is exactly same with one of the wild-type tRNA. Therefore, this 
experiment confirmed that the methylation occurred on position 37 of yeast 
mitochondrial tRNAs (Hou et al., 2006).  
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Figure 6.3:  Primer extension demonstrates methylation of yeast mitochondrial tRNA. 
Total tRNA (cytoplasmic + mitochondrial) from wild-type (Newton et al.) 
or trm5 cells was incubated in the methyltransferase assay with or without 
MBP-Trm5 as indicated. 32P-Labeled primers specific for yeast 
mitochondrial initiator tRNAMetf (Met, lanes 1–3) or mitochondrial tRNAPhe 
(Phe, lanes 4–6) were then annealed and primer extension reactions 
performed. The arrows indicate the primer extension termination products 
caused by the presence of m1G for tRNAMet (left) or tRNAPhe (right). This 
figure has been published as figure 2 in Lee, C. et al (2007) J.Biol.Chem, 
282, 27744-27753. 
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To confirm whether the termination product obtained by the reverse transcriptase 
after methylation with MBP-Trm5 protein is A38 where it is just ahead of G37 site, the 
primer extension experiment was applied to perform the dideoxyribonucleotide 
triphosphate DNA sequencing. The mitochondrial initiator tRNA primer was annealed to 
∆trm5 tRNA, and then the reverse transcriptase reaction was carried out in the presence 
or absence of the four different ddNTPs. The termination product observed in wild-type 
yeast tRNA corresponds to dideoxy T incorporation which is complementary to A38 
(Figure 6.4). Therefore, this experiment confirmed that the methylation of mitochondrial 
initiator tRNA occurred at guanosine position 37.  
The product created by Trm5 is m1G confirmed by chromatographic analysis of 
mitochondrial tRNAs. The synthetic tRNAMetf which was made by in vitro transcription 
was incubated with MBP-Trm5 and [3H]AdoMet. The radiolabeled product was 
hydrolyzed by nuclease P1, phosphodiesterase I, and alkaline phosphatase. The reverse 
phase HPLC was used to analyze products. A UV-absorbing compound in the 
hydrolysate co-elutes with a synthetic m1G standard (Figure 6.5). Fractions of eluate were 
monitored by liquid scintillation counting, and m1G peak in UV absorption profile 
corresponds to the maximum peak of radioactivity, indicating that the product of Trm5 
methylation is m1G.  
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Figure 6.4:  Mitochondrial tRNAMetf is methylated at G37 in wild-type tRNA. The 32P-
labeled primer specific for tRNAMetf was annealed to wild-type yeast tRNA 
(Newton et al.) or to ∆trm5 tRNA as indicated. The latter sample was then 
divided into 5 aliquots, each containing dNTP and MMLV-RT. To samples 
3-6, dideoxynucleoside triphosphates were added. After the reverse 
transcriptase reaction, the samples were electrophoresed on a 10% 
polyacrylamide-urea gel and analyzed by phosphorimaging. Lane 1, wild-
type S. cerevisiae tRNA; lanes 2-6, ∆trm5 tRNA with ddNTPs as indicated. 
The band corresponding to ddT incorporation complementary to A38 is 
indicated as arrow. This figure has been published as supplementary figure 3 
in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753. 
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Figure 6.5:  MBP-Trm5 catalyzes guanosine methylation in synthetic tRNAMet to 
produce 1-methylguanosine (m1G). A synthetic tRNAMet transcript (720 
pmol) was incubated with MBP-Trm5 and [3H-methyl]AdoMet at 37 °C for 
40 min. The ethanol-precipitated product was enzymatically hydrolyzed, 
and the nucleoside components were separated by reversed phase HPLC. 
The UV absorbance profile (top panel; in milliabsorbance units) shows an 
m1G peak that corresponds to the maximum peak of radioactivity measured 
by liquid scintillation counting (bottom panel; in cpm). This figure has been 
published as figure 3 in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753. 
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6.4 Mitochondrial localization of Trm5p 
At least based on the in vitro results, it was determined that the Trm5p 
methyltransferase is able to methylate the N1 of guanosine at position 37 in 
mitochondrial tRNAs such as tRNAMetf and tRNAPhe. If Trm5p is responsible for the 
methylation of these mitochondrial tRNAs, the enzyme must also be present in 
mitochondria. To test this possibility, the commercially available S.cerevisiae strain 
EY0986/TRM5-GFP was used. This strain contains a GFP tag at the C-terminus of TRM5 
gene which is under the control of the endogenous TRM5 promoter. The cells were grown 
in a semisynthetic galactose medium and fractionated by differential centrifugation into 
cytoplasmic and mitochondrial fractions. Both were analyzed by immunoblotting with 
antibodies against GFP (Figure 6.6). It showed that Trm5-GFP is localized to both the 
cytoplasm and mitochondria (Figure 6.6A). It also showed that the cytoplasmic protein 
migrated slightly faster than the mitochondrial protein. Antibodies against Hsp60, a 
mitochondrial matrix marker, were used as a control eliminating the possible 
contamination between the two fractions. Proteinase K treatment showed that the 
mitochondrial TRM5-GFP was protected from the enzymatic digestion as Hsp60 was. 
When Triton X-100 was introduced to the mitochondria to solubilize all membranes, 
TRM5-GFP showed similar localization with a matrix marker, Hsp60. These data 
indicate that the single TRM5 gene encodes a protein which is localized to both the 
cytoplasm and the mitochondrial matrix.   
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6.5 Mapping of TRM5 Transcript 
To determine where the transcriptional start site of the TRM5 gene is, RNA ligase 
mediated RACE experiment (Experiment produces 5.5) was used to explore the 5’end of 
the TRM5 transcript. Ten μg of yeast total RNA was used, and the experiment was 
performed by reverse transcriptase. The first round of PCR by using “outer” primers 
showed no detectable specific product. Two μl of the outer PCR product were used for 
the second round of PCR with “inner” primers (nested primers), producing a specific 
product of around 400 bp. This performance was done several times to yield more PCR 
products. The final PCR products were gel-purified and subcloned into a pBluescript II 
KS(+/-) vector. Ten clones were screened by PCR and sequenced. Three of the ten clones 
exhibited the same 5’-end 24 bp upstream (-24) of the first AUG start codon (Figure 6.7). 
Two of them showed the same 5’-end 18 bp (-18) upstream of the start codon. Likewise, 
two of them exhibited at 12 bp (+12) downstream of the AUG codon, and three of them 
at 21 bp downstream of the AUG codon (+21). Four potential transcriptional start sites of 
the TRM5 gene were revealed at -24, -18, +12, and +21 (Figure 6.7).  
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Figure 6.6:  Trm5p shows dual localization to cytoplasm and mitochondria. A, 
cytoplasmic (C) and mitochondrial (M) fractions prepared from cells 
expressing Trm5-GFP were electrophoresed on a 10% SDS-polyacrylamide 
gel and immunoblotted with antibodies against GFP. Each lane contains 75 
µg of protein. Locations and size (kDa) of molecular mass markers are 
shown on the right. Full-length Trm5p (499 amino acids) fused to GFP (238 
amino acids) would have a molecular mass of 83.3 kDa. A duplicate gel 
was immunoblotted with antibodies against mitochondrial marker Hsp60 as 
a control. B, mitochondria (50 µg protein) were incubated with or without 
proteinase K (PK, 1 mg ml–1) in the presence or absence of 0.5% Triton X-
100 and immunoblotted with antibodies against GFP. A duplicate gel was 
immunoblotted with antibodies against mitochondrial matrix marker Hsp60 
as a control. This figure has been published as figure 4 in Lee, C. et al 
(2007) J.Biol.Chem, 282, 27744-27753. 
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Figure 6.7:  5' -UTR and potential transcription and translation start sites of the yeast 
TRM5 gene. Nucleotides are numbered with the A of the first ATG codon as 
1. Codons are numbered with the first potential ATG start codon as 1. In-
frame ATG codons (codons 1, 20, 34, and 48) are indicated in bold type. 
The arrows beginning at nucleotides –24, –18, +12, and +21 indicate 
transcriptional start sites based on 5'-RACE (this work). The diamond at –94 
indicates the 5' end of the TRM5 transcript mapped using a high density 
oligonucleotide array (David et al., 2006). This figure has been published as 
figure 5 in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753.   
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6.6 Identification of translation start sites of TRM5 in vivo  
“There are several mechanisms known that can generate dual localization of a 
protein encoded by a single gene (Karniely and Pines, 2005; Martin and Hopper, 1994). 
In most cases, alternative translational start sites result in alternative N-terminal 
sequences of the proteins, which in turn targets the proteins to different compartments 
(e.g. cytoplasm versus mitochondria). Inspection of the 5' end of the proposed TRM5 
ORF reveals four in-frame AUG codons (positions 1, 20, 34, and 48) within the first 48 
codons (Figure 6.7). To try to identify the translational start site(s) used in vivo, we 
constructed three N-terminal truncation mutants of Trm5p, in which amino acids 1–19, 1–
33, or 1–47 were deleted (Figure 6.8). The 5'-UTR up to position –1 adjacent to the first 
AUG codon remained intact in each construct. Each construct was expressed from the 
single-copy vector pRS415 (LEU2 vector), driven by the TRM5 promoter. These pRS415 
constructs were transformed into the trm5 haploid mutant strain (DLY1) harboring a 
wild-type copy of TRM5 on pRS416 (URA3 vector). Leu+ Ura+ transformants were then 
streaked onto yeast minimal glucose (YMD) or ethanol+glycerol (YPEG) plates 
containing 5-fluoroorotic acid to evict the wild-type TRM5 gene on the pRS416 plasmid. 
The 1–19 and 1–33 constructs support growth on glucose as well as the full-length 
TRM5 construct, whereas cells expressing the 1–47 construct failed to grow (Figure 
6.9). Likewise, all the constructs support growth on the nonfermentable ethanol + 
glycerol plate except the 1–47 construct (Figure 6.9). Thus, the first 33 amino acids of 
the proposed TRM5 ORF are not necessary for the expression of a functional Trm5p, 
because trm5 null mutants exhibit a severe growth defect on glucose (Bjork et al., 2001). 
The simplest interpretation of these data is that translation initiates at the third AUG 
codon (codon 34) to produce a Trm5p that functions in the cytoplasm to methylate 
cytoplasmic tRNAs”. 
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“To determine the translation start site of the mitochondrial form of Trm5p, we 
examined the methylation status of mitochondrial tRNAs in DLY1 cells expressing the 
1–19 and 1–33 truncation constructs. The primer extension product indicative of 
methylation at position 37 was undetectable in mitochondrial tRNAMetf and tRNAPhe 
isolated from the two truncation mutants (Figure 6.10). Overexposure of the gel revealed 
a faint signal in the tRNAMetf isolated from the 1–19 mutant (lane 3), but this was not 
reproducable in subsequent experiments. These data suggest that initiation at either the 
first or second AUG codon can produce a functional mitochondrial form of Trm5p, 
although use of the second AUG (codon 20) is much less efficient”. 
 
6.7 Oxygen consumption of Trm5p truncation mutants 
“Although neither the 1–19 nor 1–33 truncation mutants showed a growth 
defect on YPEG plates, the lack of detectable methylation prompted us to take a closer 
look at mitochondrial function in these two mutants. Oxygen consumption rates were 
measured on DLY1 cells expressing either the full-length or the 1–19 or the 1–33 
truncated TRM5p. As shown in Figure 6.11, cells expressing the 1–33 construct 
exhibited a significantly lower rate of oxygen consumption compared with cells 
expressing full-length TRM5. Cells expressing the 1–19 construct exhibited a smaller, 
nonsignificant decrease in oxygen consumption rate”. 
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Figure 6.8:  Three N-terminus truncation mutants of TRM5. The four potential 
translational start sites are colored as red.  
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Figure 6.9:  Growth phenotypes of Trm5p truncation mutants. A trm5 haploid strain 
(DLY1) harboring full-length TRM5 on a URA3 plasmid (pRS416-TRM5) 
was transformed with various TRM5 constructs in LEU2 plasmids 
(pRS415). Leu+ transformants were then streaked onto 5-fluoroorotic acid 
(5-FOA)/YMD or 5-fluoroorotic acid/YPEG plates and incubated at 30 °C 
for 4 or 5 days, respectively. Sector 1, full-length TRM5 (pRS415-TRM5); 
sector 2, pRS415- 1–33TRM5; sector 3, pRS415- 1–19TRM5; sector 4, 
pRS415- 1–47TRM5; sector 5, pRS415 empty vector (negative control). 
This figure has been published as figure 6A in Lee, C. et al (2007) 
J.Biol.Chem, 282, 27744-27753. 
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Figure 6.10: Primer extension analysis of the methylation status of mitochondrial    
tRNAMetf and tRNAPhe in Trm5p truncation mutants. Total tRNA was 
obtained from wild-type (Newton et al.) cells, strain DLY1 ( trm5), or 
DLY1 harboring plasmids pRS415- 1–19TRM5 ( 1–19) or pRS415- 1–
33TRM5 ( 1–33). 32P-Labeled primers specific for yeast mitochondrial 
initiator tRNAMetf (Met, lanes 1–4) or mitochondrial tRNAPhe (Phe, lanes 5–
8) were annealed, and primer extension reactions were performed. The 
arrows indicate the primer extension termination products caused by the 
presence of m1G for tRNAMet (left) or tRNAPhe (right). This figure has been 
published as figure 7 in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-27753. 
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Figure 6.11: Oxygen consumption of strain DLY1 harboring various TRM5 constructs 
grown in minimal medium with glucose as carbon source (YMD). All of the 
rates (nmol oxygen min–1) were normalized to the A600 of the culture, and 
the mean oxygen consumption rate (nmol min–1 A600–1) of the pRS416-
TRM5 (wild-type) culture was assigned a value of 1. Each column 
represents the mean ± the S.E. from two independent experiments (n = 2). *, 
p < 0.02 versus pRS416-TRM5, unpaired t test. This figure has been 
published as figure 6B in Lee, C. et al (2007) J.Biol.Chem, 282, 27744-
27753. 
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6.8 DISCUSSION 
“At least eight mitochondrially encoded tRNAs are known to be methylated in the 
N1 position of G37 in vivo (Dunin-Horkawicz et al., 2006), yet the enzyme(s) responsible 
for modification of these mitochondrial tRNAs has not been previously identified. We 
have shown here that the tRNA (guanine-N1-)-methyltransferase encoded by the yeast 
TRM5 gene is responsible for methylation of G37 in mitochondrial initiator tRNA 
(tRNAMetf). Its function in the yeast cytoplasm has been shown before (Bjork et al., 
2001). Similar to the human Trm5p (Brule et al., 2004), the recombinant yeast enzyme 
uses S-adenosyl-L-methionine as a methyl donor and is specific for the N1 in the G 
residues at position 37 in natural tRNAs. In particular, yeast Trm5p efficiently methylates 
G37 in mitochondrial tRNAMetf, which contains U at position 36. Thus, like the human 
Trm5p and in contrast to prokaryotic TrmD (Brule et al., 2004; Takeda et al., 2006), the 
yeast enzyme appears to tolerate any nucleotide at position 36. The product of the 
reaction catalyzed by yeast Trm5p was shown to be m1G by HPLC”.  
“Because Trm5p is also responsible for m1G37 modification of cytoplasmic 
tRNAs (Bjork et al., 2001), the enzyme must have a dual localization to both the 
cytoplasm and the mitochondria. This was confirmed in yeast using a GFP-tagged version 
of Trm5p and antibodies against GFP. Proteinase K digestion showed that the 
mitochondrial form resides in the mitochondrial matrix, where it can access the 
mitochondrially encoded tRNAs. Early work in yeast indicated the existence of two tRNA 
(guanine-N1-)-methyltransferases in that organism, specific for tRNA sites 9 and 37 
(Sindhuphak et al., 1985; Smolar et al., 1975). These two distinct enzymes are now 
known to be encoded by TRM10 (Jackman et al., 2003) and TRM5 (Bjork et al., 2001), 
respectively. Sindhuphak et al. even detected two peaks of m1G37 methyltransferase 
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activity on a tRNA affinity column, foreshadowing the two forms of Trm5p (cytoplasmic 
and mitochondrial) reported here”. 
“The predicted amino acid sequence of Trm5p reveals four potential AUG start 
codons in the N terminus (codons 1, 20, 34, 48) (Illustration 6.2). Growth analysis 
(Figure. 6.8) revealed that a Trm5p active in the cytoplasm (as determined by normal 
growth on glucose) could be obtained with a construct lacking amino acids 1–33, whereas 
production of a Trm5p active in the mitochondria (as determined by the methylation 
status of mitochondrial tRNAs) required these first 33 amino acids. Oxygen consumption 
assays (Figure. 6.10) revealed decreased respiration efficiency for both the 1–19 and 
1–33 constructs, although only the 1–33 construct was significantly reduced. These 
data suggest a model in which the mitochondrial form initiates at the first AUG codon, 
producing a protein with an N-terminal mitochondrial targeting sequence. Helical wheel 
analysis indicates that residues 1–19 could fold into an amphipathic -helix, with both a 
hydrophobic and a basic face (cti.itc.virginia.edu/~cmg/Demo/wheel/wheelApp.html). 
Our data cannot deduce whether or where the presequence is cleaved upon translocation 
into the mitochondrion. PSORT II analysis (psort.hgc.jp/form2.html) predicts 
mitochondrial localization only for the full-length ORF; initiation at any of the 
downstream AUG codons predicts a cytoplasmic localization. In our model, the shorter 
cytoplasmic form initiates at the third AUG codon, producing a protein lacking a 
mitochondrial targeting sequence. This model is consistent with the slightly larger size of 
the mitochondrial form compared with the cytoplasmic form on SDS gels (Figure 6.6). 
However, we cannot rule out the possibility that a non-AUG codon is used to initiate 
translation, as occurs in the dual localization of the GRS1 and ALA1 gene products 
(Chang et al., 2006; Chang and Wang, 2004). Attempts to address this question with N-
terminal amino acid sequencing of Trm5p isolated from yeast were not successful”.  
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“Mapping of the 5' ends of the TRM5 transcript suggests how this differential 
translation initiation might occur. We observed two sets of transcriptional start sites: 
nucleotides –24 and –18 (upstream of the first AUG codon) and nucleotides +12 and +21 
(between the first and second AUG codons). Transcriptional initiation at the upstream 
sites would allow translation to initiate from the first AUG, producing a protein with a 
mitochondrial presequence to direct translocation into the mitochondrion. Transcriptional 
initiation at the downstream sites would force translation initiation to the second or third 
AUG codon, bypassing the mitochondrial presequence, to yield a cytoplasmic protein”.  
“A transcription map of the yeast genome obtained using a high density 
oligonucleotide array (David et al., 2006) indicates the 5' end of the TRM5 transcript at 
nucleotide –94, although this mapping method would not detect transcripts from the same 
gene with shorter 5' ends, such as those we observed with 5'-RACE mapping. Because we 
were unable to obtain reproducible results with ribonuclease protection mapping, the 
transcriptional start site(s) of the TRM5 gene remain equivocal”.  
“It is also possible that the two Trm5p isoforms are produced from the same 
transcript, as a result of "leaky" ribosome scanning. Leaky scanning can occur when the 
first AUG resides in a suboptimal sequence context, leading to its inefficient utilization as 
initiator and shifting initiation to an AUG at a downstream location. This mechanism 
occurs in at least four yeast genes that produce two protein isoforms from a single 
transcript: MOD5 (Slusher et al., 1991), CCA1 (Wolfe et al., 1994), GRS1 (Chang and 
Wang, 2004), and ALA1 (Chang et al., 2006). Indeed, the sequence context of the first 
AUG (5'-UUGCAUGAAA-3') is a very poor match to the consensus for yeast genes 
(Cigan and Donahue, 1987); the sequences surrounding the second and third AUGs are 
much closer to the consensus”. 
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“Finally, it is possible that mRNA localization plays a role as well. Total RNA 
isolated from a crude mitochondrial fraction was enriched for TRM5 mRNA (data not 
shown). A number of nuclear-encoded mitochondrial proteins are known to be translated 
from mitochondria-associated mRNAs (Garcia et al., 2007), and the TRM5 transcript has 
a fairly high mitochondrial localization of mRNA index level of 63 (Marc et al., 2002). 
Thus, it may be that the mitochondrial form of Trm5p is translated on cytoplasmic 
ribosomes bound to the surface of mitochondria”.  
“It is likely that the m1G37 tRNA modification plays the same role in 
mitochondria as it does in cytoplasmic and bacterial translation systems, i.e. reading 
frame maintenance (Bjork et al., 1989). The results from the truncation mutants showed 
that m1G37 methylation of mitochondrial tRNAs is not essential for mitochondrial protein 
synthesis, because the 1–33 mutant, which lacks this modification, can still respire (as 
evidenced by growth on ethanol + glycerol; Figure 6.8). However, loss of mitochondrial 
m1G37 tRNA methylation did correlate with decreased oxygen consumption (Figure 
6.10), indicating a defect in oxidative phosphorylation. This suggests that the efficiency 
or accuracy of mitochondrial protein synthesis is decreased in cells lacking m1G37 
methylation of mitochondrial tRNAs, probably because of accumulation of translational 
frameshift mutations”.  
“This same phenomenon is also seen in mutants of the MSS1 and MTO1 genes 
involved in 2-thiolation of the wobble position in yeast mitochondrial tRNAs (Umeda et 
al., 2005). Thus, whereas lack of these tRNA modifications may not cause observable 
growth defects in a laboratory setting, they can cause decreased mitochondrial translation 
efficiency. If these tRNA modifications provide even the slightest growth advantage to 
the organism, they would be retained, reflecting what has been called the ruthless 
delicacy of selection”.  
 108
“The bacterial ancestor of mitochondria probably had a full complement of tRNA-
modifying enzymes. During their organellar evolution, mitochondria have maintained 
distinct transcription, translation, and tRNA genes, even as their aminoacyl-tRNA 
synthetases and RNA-modifying enzymes were displaced by nuclear-encoded eukaryotic 
forms. Similar to the TRM1 gene, whose product introduces the N2,N2-
dimethylguanosine modification in cytoplasmic and mitochondrial tRNAs (Martin and 
Hopper, 1994), TRM5 encodes multiple targeting sequences. This organization simplifies 
and consolidates the RNA-modifying systems but constrains the evolution of RNA 
processing and translation in both the nucleus and the mitochondria”.  
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Appendix A 
Abbreviations 
                              
AdoMet    S-adenosylmethionine 
Amp     ampicillin   
bp     base pair      
BSA     bovine serum albumin 
C1     one-carbon 
CH+-THF    5,10-methenyltetrahydrofolate 
10-CHO-THF    10-formyltetrahydrofolate 
cpm     counts per minute 
ddH2O     distilled, deionized water 
ddNTP     dideoxyribonucleotide triphosphate 
DMSO     dimethyl sulfoxide 
dNTP     deoxyribonucleotide triphosphate 
DTT     dithiothreitol 
ECL     enhanced chemiluminescence 
EDTA     ethylenediamine tetraacetic acid 
fMet-tRNA    formylmethionyl-tRNA 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2- 
ethanesulfonic acid) 
His histidine 
HOAc Acetic acid 
HPLC high performance liquid chromatography 
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HRP horseradish peroxidase 
IAA Isoamyl alcohol 
GFP green fluorescent protein 
IPTG isopropyl-β-D-thiogalactopyranoside 
kb kilo base pair 
kDa kilo Dalton 
KOAc potassium acetate 
LiOAc lithium acetate 
MBP maltose binding protein 
nt nucleotide 
OD optical density 
ORF open reading frame 
PAGE  polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PEG polyethylene glycol 
RACE rapid amplification of cDNA ends 
RbCl rubidium chloride 
RLM-RACE RNA ligase-mediated rapid amplification of 
cDNA ends 
RNase ribonuclease 
RT reverse transcriptase 
SDS sodium dodecyl sulfate 
SOE splice overlap extension 
TBS Tris-buffered saline 
TEV tobacco etch virus 
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THF tetrahydrofolate 
UTR untranslated region  
YT Yeast extract and Tryptone 
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Appendix B 
Materials 
                              
Material       Manufacturer 
Agarose Invitrogen Life TechnologiesTM (Carlsbad, 
CA) 
Amino acids Calbiochem Corp. (San Diego, CA) 
Ampicillin Sigma-Aldrich Co. (St.Louis, MO) 
Amylose Resin New England Biolabs (Ipswich, MA) 
Anti-GFP antibodies AnaSpec (San Jose, CA) 
Anti-HA antibodies Covance Inc. (Trenton, NJ) 
Anti-Hsp60 antibodies IMGENEX (San Diego, CA) 
BSA Sigma-Aldrich Co. 
dNTPs Invitrogen Life Technologies 
ECL Western blotting reagents GE Healthcare Bio-Sciences (Piscataway, 
NJ) 
EDTA Sigma-Aldrich Co. 
DTT Sigma-Aldrich Co. 
Ethanol AAPER Alcohol and Chemical Co. 
Fast-LinkTM DNA Ligation Kit Epicentre® Technologies (Madison, WI) 
FirstChoiceTM  RLM-RACE Kit Ambion, Inc. (Austin, TX) 
Formic acid EM Science (Gibbstown, NJ) 
Geneticin® (G418 Sulfate) American Bioanalytical (Natick, MA) 
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His-Bind Metal Affinity Resin Novagen (Gibbstown, NJ)  
HRP-goat anti-mouse or rabbit IgGγ Zymed Laboratories, Inc. (San Francisco, 
CA) 
Imidazole Sigma-Aldrich Co. 
IPTG Research Products International Corp. (Mt. 
Prospect, IL) 
KOD Hot Start DNA polymerase Novagen (Gibbstown, NJ) 
Lyticase Sigma-Aldrich Co. 
Yeast Media ingredients Difco Laboratories (Sparks, MD) 
2-mercaptoethanol Sigma-Aldrich Co. 
Methanol Sigma-Aldrich Co. 
Nitrocellulose membrane Schleicher and Schuell Bioscience, Inc. 
(Keene, NH) 
Oligonucleotides Integrated DNA Technologies, Inc. 
(Coralville, VA) 
PAGE supplies Bio-Rad Laboratories, Inc. (Hercules, CA) 
pBluescript KS (+/-) Stratagene® (La Jolla, CA) 
[α-32P]dATP PerkinElmer Life Sciences (Wellesley, MA) 
Phenol:CHCl3:IAA (25:24:1) Ambion, Inc. (Austin, TX) 
Phenylmethylsulfonyl fluoride Sigma-Aldrich Co. 
Protease inhibitor cocktail Tablet Roche Applied Science (Indianapolis, IN) 
Protein A Sepharose beads Pierce (Rockford, IL) 
Protein assay dye reagent Bio-Rad laboratories, Inc. 
DNA purification kits QIAGEN Inc. (Valencia, CA) 
Restriction endonucleases New England Biolabs (Ipswich, MA) 
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Rosetta 2 (DE3)pLysS E.coli strain Novagen 
S-adenosylmethionine Sigma-Aldrich Co. 
Strip-EZTM PCR Kit Ambion, Inc. 
Taq DNA polymerase Invitrogen Life Technologies 
Triton X-100 Beckman® Analytical Chemicals 
XL1-Blue E.coli strain Stratagene 
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Appendix E 
Protocols 
 
        Protocol 1: Standard Polymerase Chain Reaction (PCR) 
                     
The Vent DNA polymerase (New England Biolabs) was used for the majority of 
the PCR reactions. Cloning experiments were performed with KOD Hot Start DNA 
polymerase (Novagen) which has 3’ to 5’ exonuclease proofreading activity with high 
fidelity.  
 
PCR on yeast genomic DNA: 
A. Mixture: (50μl total reaction volume) 
1. 5 μl of 10 x PCR amplification buffer (supplied with enzyme) 
2. 5 μl of 2.5 mM dNTPs (supplied with enzyme) 
3. 2 μl of MgSO4 (1mM final concentration, supplied with enzyme) 
4. 1 to 100 ng template DNA 
5. 1.5 μl of 10 μM 5’ primer  
6. 1.5 μl of 10 μM 3’ primer 
7. 1μl of 1U/μl KOD Hot Start DNA Polymerase 
8. Sterile ddH2O to a final volume of 50 μl 
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B. Amplification steps in a thermal cycler: 
1. 94oC, 2 min.; 1 cycle 
2. 94oC, 15 sec.; annealing at 55oC, 30 sec.; elongation at 68oC, 1 min per 1kb;  
  30 cycles 
3. Extend 68oC, 10 min; 1 cycle 
 
 
PCR on DNA plasmid templates: 
A. Mixture: (50μl total reaction volume) 
1. 5 μl of 10 x PCR amplification buffer (supplied with enzyme) 
2. 4 μl of 2.5 mM dNTPs  
3. 10 to 100 ng template DNA 
5. 1 μl of 10 μM 5’ primer  
6. 1 μl of 10 μM 3’ primer 
7. 1 μl of 1U/μl Vent DNA Polymerase 
8. Sterile ddH2O to a final volume of 50 μl 
 
B. Amplification steps in a thermal cycler: 
1. 94oC, 3 min.; 1 cycle 
2. 94oC, 30 sec.; annealing at 55oC, 30 sec.; elongation at 72oC, 1 min per 1kb;  
  30 cycles 
3. Extend 72oC, 7 min.; 1 cycle 
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Protocol 2: Yeast Transformation 
                     
This method was originally derived from the Gietz Laboratory (University of 
Manitoba, Winnipeg, Manitoba, CANADA) (Gietz and Woods, 2002), and modified for 
our own purposes.  
 
1. Start a 5 ml culture of yeast in minimal medium or rich medium at 30oC overnight. 
2. Transfer cells at OD600 of 1.0 to 25 ml culture of yeast and incubate at 30oC 
  overnight 
3. Collect cells by centrifugation at 3,000 x g for 5 min., at room temperature 
4. Resuspend pellets in 5 ml of pre-warmed rich media and take 0.5 ml of resuspended 
  cells.  
5. Transfer the cells into pre-warmed 50 ml of rich medium and incubate it at 30oC  
  until the cells reach 3 x 109. (Usually, it takes 3 hours) 
6. Wash the cells in half volume of ddH2O and resuspend pellets in 3 ml of  
  100 mM LiOAc.  
7. Aliquot 100 μl of cell suspension into a 1.5 ml microcentrifuge tube for each   
  transformation.  
8. Incubate cell suspension at 30oC for 15 min.  
9. Microcentrifuge at 10,000 x g for 1 min. and take off the supernatant with 
  a micropipette. 
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10. Add the transformation mix to each tube in the following order. 
      a. 240 μl 50% (v/v) PEG, filter sterilized 
      b. 36 μl 1 M LiOAc, filter sterilized 
      c. 10 μl 10 mg/mL salmon sperm DNA (It should be boiled for 5 min before use) 
      d. 100 ng to 5 μg of DNA plasmid 
      e. 36 μl sterile ddH2O  
 
11. Vortex mixture vigorously for at least 1min. and incubate at 30oC for 30 min.  
12. Incubate mixture at 42oC for 15 min (Invert tubes 5 times every 2.5 min) 
13. Microcentrifuge at 10,000 x g for 1 min. and remove the supernatant with  
   a micropipette. 
14. Add 150 μl sterile ddH2O into tubes and spread cells on the selective media plates 
15. Incubate them at 30oC for at least 3 days.  
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Protocol 3: Immunoblotting 
(Tibbetts and Appling, 2000) 
 
                     
Solutions:  
1. 20X Transfer Buffer (200ml) 
  0.2 M Tris base (4.84 g) 
2M glycine (30.03 g) 
200 ml of 20 X transfer buffer mixed with 400 ml of methanol and 3400 ml of 
ddH2O to prepare 1 X transfer buffer 
 
 
2. 20X TBS (100ml) 
  0.2 M Tris base (2.42 g) 
 3 M NaCl (17.53 g) 
 80 ml of ddH2O, pH 8.0 with HCl 
 ddH2O to final volume of 100 ml (if desired, autoclave) 
 dilute 20-fold to prepare 1X TBS (final concentration of 10 mM Tris-HCl,  
                                 150 mM, NaCl, pH 8.0) 
 
  
3. 1X TBST 
  Add 0.05% of Tween-20 to 1 X TBS 
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Protocol: 
 
1. Run protein samples as well as Bio-Rad protein markers on a SDS-PAGE gel. 
2. Soak the gel in 1 X transfer buffer for 2 min. 
3. Cut a piece of nitrocellulose membrane to fit the gel and two pieces of  
  Whatman 3MM filter paper with a slightly larger size than the membrane 
4. Wet the nitrocellulose membrane in 1X transfer buffer briefly and place it on top 
  of the gel. Do not forget to get rid of any air bubbles in between. 
5. Make a sandwich of the gel plus membrane between two pieces of filter paper.  
  Make sure the gel is closer to the black (cathode) and membrane to the red (anode).  
6. Assemble the electroblot apparatus (Bio-rad) in the cold room and run the transfer  
  at 250mA (~200V) for 90 min while stirring. 
7. Disassemble the apparatus and wash the membrane in ddH2O.  
8. Block the membrane with 2% dry milk powder (H.E.B) in TBS for 1 hour  
  with shaking.  
9. Remove the blocking solution and add primary antibody appropriately diluted in  
  1 X TBS with 1% dry milk powder [The antibodies and dilutions used are given under  
  Experimental procedures]. Incubate with shaking for 1 hour. 
10. Wash the membrane with TBST (three times, 5 min each) 
11. Add secondary antibody in a 1:2000 dilution in TBST and incubate with shaking  
   for 1 hour.  
12. Wash the membrane twice in TBST for 5 min each. 
13. Wash the membrane twice in TBS for 5 min each. 
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14. Rinse the membrane with ddH2O immediately before using an enhanced 
   chemiluminescence (ECL) detection system. 
15. In a dark room, combine the ECL Plus Western Blotting reagents (GE  
   Healthcare Bio-Sciences), Reagent 1 with Reagent 2 together in a 40:1 ratio and  
   put it on the membrane. Incubate for 5 min. 
16. Remove the reagents from the membrane and place it in a transparency sheet.  
17. Visualize the signals in a Kodak Image Station 4000R.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125
 
Protocol 4: Isolation of mitochondria from S. cerevisiae  
 
  
Semisynthetic galactose medium (per 1L) 
 3 g yeast extract 
 10 g galactose 
 0.8 g (NH4)2SO4 
 0.7 g MgSO4·7H2O 
 0.5 g NaCl 
 1 g KH2PO4 
 0.4 g CaCl2 
 5 mg FeCl3·6H2O 
 
1. Start a 25 ml culture of yeast in semisynthetic galactose medium at 30oC for growth 
  overnight with shaking.  
2. Transfer the culture into a flask containing 2 L galactose medium and incubate  
  at 30oC overnight with shaking.  
3. Harvest cells at 5,000 rpm for 10 min and wash with ice-cold ddH2O three times. 
4. Resuspend cell pellets in 60 ml of 0.1 M Tris-HCl, pH 9.3, 10 mM DTT and incubate 
  at 30oC for 10 min with shaking.  
5. Centrifuge at 3,500 rpm for 10 min.  
6. Resuspend cell pellets in 100 ml 1.2 M sorbitol, 10 mM phosphate buffer, pH 7.4  
  and incubate at 3,500 rpm for 10 min. 
7. Resuspend cell pellets in 40 ml 1.2 M sorbitol, 10 mM phosphate buffer, pH 7.4 and  
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  add 40 mg of lyticase. 
8. Incubate at 30oC for 90 min. and then centrifuge at 4,200 rpm for 10 min.  
9. Resuspend cell pellets in 7 ml of 0.6 M sorbitol, 20 mM Tris-HCl, pH 7.4,  
  2 mM EDTA and homogenize cells with a douncer with 15 strokes.  
10. Centrifuge at 4,200 rpm for 10 min. Keep the supernatant. 
11. Resuspend cell pellets in 7 ml of same buffer above and homogenize cells again.  
   Centrifuge at 4,200 rpm for 10 min and combine supernatants from both 
   homogenization together. 
12. Centrifuge at 10,000 rpm for 15 min.  
13. Keep supernatants as a cytosolic fraction, and resuspend the mitochondrial pellets  
   in 400 μl of 0.6 M sorbitol, 20 mM HEPES, pH 7.4.  
14. Measure the protein concentration in the Bradford assay (Bradford, 1976).  
15. Aliquot the resuspended mitochondria and store at -80oC.  
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Protocol 5: Splice Overlap Extension (SOE) PCR 
                     
This method was originally devised by Dr. David E. Graham (University of Texas 
at Austin, TX), and modified for our own purposes.  
 
1. Amplify separate DNA fragments using a standard PCR method. 
2. Purify PCR products using a PCR purification Kit (Qiagen) and gel-purify each  
  product. 
3. Prepare SOE PCR  
 5 μl of 10x PCR buffer for the DNA polymerase 
 5 μl of dNTPs (final concentration of 0.2 mM) 
 3 μl of MgSO4 (final concentration of 1.5 mM) 
 50 to 100 ng each PCR product  
 1 μl of KOD Hot Start DNA Polymerase (final concentration of 0.02 U/μl) 
 sterile ddH2O to a final volume of 50 μl 
  - Note: Do not add any primers in this stage 
4. Run a program in a thermocycler as follows. 
 94oC, 3 min; 1cycle 
 94oC, 30 sec; 55oC, 30 sec for annealing; 72oC, 2 min; 5 cycles 
  - Note: two DNA fragments should be overlapping by at least 20 nucleotides.  
   Annealing and elongation times are adjustable based on DNA fragments (1kb/1min).  
5. Add 2 μl of each terminal primers (final concentration of 0.8 μM) 
6. Continue the program for the rest of the PCR program as follows. 
 94oC, 30 sec; 55oC, 30 sec; 72oC, 2 min; 25 cycles 
7. Analyze the PCR product on an agarose gel.  
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Protocol 6: Transformation of RbCl-Competent E.coli Cells 
(Hanahan, 1985) 
 
                     
Solutions:  
1. TFB1 
  30 mM KOAc, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2,   
      15% (w/v) glycerol, pH 5.8, sterilize by filtration (HOAc used to adjust the pH) 
 
2. TFB2 
  10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% (w/v) glycerol, pH 6.5,  
      sterilize by filtration (adjust the pH with KOH) 
 
Protocols:  
1. Make competent cells 
    a. Inoculate a single colony of E.coli XL1-B into 5 ml of YT medium.  
      Incubate at 37oC overnight. 
    b. Transfer the cell suspension into 250 ml culture of YT containing 20 mM MgSO4.  
      Incubate at 37oC until OD600 of 0.4 ~ 0.6 is reached. 
    c. Centrifuge cells at 4oC for 5 min at 5,000 x g.  
    d. Resuspend pellets gently in 100 ml TFB1. 
    e. Incubate for 5 min on ice. 
    f. Centrifuge at 4oC for 5 min at 5,000 x g. 
    g. Resuspend pellets gently in 10 ml TFB2 
    h. Incubate for 60 min on ice. 
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    i. Aliquot 100 μl of cell suspension into 0.5ml Eppendorf tubes. 
    j. Freeze them right away in liquid N2.  
    
2. Transformation into RbCl-competent cells 
    a. Let cell thaw on ice for 5 min. 
    b. Add 10 ng – 500 ng of plasmid DNA 
    c. Incubate on ice for 60 min. 
    d. Heat shock at 37oC for 45 sec. 
    e. Add 200 μl of YT and incubate at 37oC for at least 30 min. 
    f. Spread cells onto selective medium plates.  
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Protocol 7: Plasmid Rescue from S. cerevisiae 
(Robzyk and Kassir, 1992) 
                     
 
Solution:  
STET:    8% sucrose, 50 mM Tris-HCl (pH 8.0), 50mM EDTA, 5% Triton X-100.  
 
 
Protocol: 
1. Start 3 ml of a yeast culture containing the plasmid in selective minimal medium 
  and grow overnight. 
2. Harvest cells at 5,000 rpm for 5 min. 
3. Resuspend the cell pellets in 100 μl of STET 
4. Add 0.2 g of washed glass beads (425-600μm; Sigma-Aldrich Co.) into  
  the cell suspension and vortex for 5min. 
5. Add another 100 μl of STET. 
6. Vortex briefly and place in boiling water for 3 min and cool the tube on ice.  
7. Centrifuge cells at 12,000 x g for 10 min in the cold room. 
8. Take 100 μl of the supernatant and place into a 1.5ml Eppendorf tube containing  
  50 μl of 7.5 M ammonium acetate. 
9. Incubate at -20oC for 1 hour. 
10. Centrifuge at 12,000 x g for 10 min in the cold room.  
11. Take 100 μl of the supernatant into 200 μl of ice-cold ethanol to precipitate the DNA.  
12. Incubate the tube on ice for 10 min. 
13. Centrifuge at 12,000 x g for 10 min in the cold room.  
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14. Remove supernatant carefully and wash pellet in 70% ice-cold ethanol. 
15. Centrifuge at 12,000 x g for 5 min and remove supernatant. Dry the resulting pellets. 
16. Resuspend pellet in 20 μl of sterile ddH2O.  
17. Do the electroporation to transform E.coli JM109 cell with the resuspended pellet.  
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Protocol 8: UV mutagenesis of yeast cells 
(Tibbetts, 2008) 
 
1. Start a 4 ml culture of yeast in minimal medium (YMD) with the appropriate  
  amino acids at 30oC overnight. 
2. Inoculate 25 ml YMD containing the amino acids with 2 ml of the overnight  
  culture and grow again at 30oC overnight until OD600 of 2.  
3. Centrifuge cells at 1,750 x g for 5 min, and resuspend in 10 ml of sterile ddH2O to  
  a density of 1-5 x 107cells /ml.  
4. Vortex for 30 sec and aliquot 1.5 ml of cells into 7 different screw-top microcentrifuge  
  tubes.  
5. Distribute each 1.5 ml of cells in pre-sterilized boats and expose to UV radiation at 6  
  sec intervals 
  - Use Stratalinker autocrosslinker (Stratagen) to sterilize boats. 
6. Try different time exposures such as 6, 12, and 18-sec. and save cells before UV  
  radiation as control. 
7. Put 750 μl each of UV-exposed cells into 2 sterile tubes and wrap with foil. 
8. Dilute each cell at each time interval and plate onto YPD plates  
9. Determine the killing efficiency relative to controls (No mutagenized cells). 
  - Cutoff threshold: 10-40% cells survival 
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